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                                           CHAPTER I 
                                  INTRODUCTION 
 
              For thousands of years human have used natural substances, especially 
plants, to relieve pain, heal wound and maintain health. Throughout the world today, 
especially in the developing countries, people recognize the value of medicinal plants 
in treating and preventing common diseases. Herbal medicine is one of the most 
important resources which can be mobilized for the attendance of WHO's goal of 
health for all by the year 2000. It has contributed significantly to man’s struggle 
against diseases and has been an important component of health care system for 
thousands of years.  
              Now, a serious world wide problem in the hospital is drug-resistant bacteria 
including Thailand. Due to indiscriminate use of antimicrobial drugs, microorganisms 
have developed resistance to many antibiotics and that have created immense clinical 
problems in the treatment of infectious diseases (Davis, 1994). The bacterial resistant 
antibiotics have several groups including β-lactam antibiotic drugs which are very 
expensive. In the past, antibiotics are used for effective treatment of many diseases, 
but now they can not cure those diseases because the bacteria can resist those drugs. 
Strains of ceftazidime-resistant Escherichia coli (CREsC), ceftazidime-resistant 
Enterobacter cloacae (CREnC) including β-lactam resistant Staphylococcus aureus 
and methicillin-resistant S. aureus (MRSA) have a posing serious problem to 
hospitalized patients and their care providers (Maharat Nakhon Ratchasima hospital, 
  
 2000; Lui, Durham, and Richards, 2000).
              MRSA are the most common organisms causing infections of the urinary 
tract, surgical wounds, skin respiratory and gastrointestinal tract including 
Escherichia coli and Enterobacter spp. (Biedenbach et al., 2004; D’A gata, 2004; 
Farr, 2002; Hull and Beck, 2004; Schaberg et al., 1190). In addition, antibiotics are 
sometimes associated with adverse effects on host which include depletion of 
beneficial gut and mucosal microorganisms, immunosuppression, hypersensitivity and 
allergic reaction. The drugs-resistant bacteria have further complicated the treatment 
of infectious diseases in immonocompromised, AIDS and cancer patients, especially 
in the case of nosocomial infections (McGaw, Jager, and Staden, 2000). There is not 
only the lost of an effective antibiotic against multi-drugs resistant bacteria, but also a 
global problem for the lost of budget for treatment of infectious diseases.  
              In the present, scenario of emergence of drug resistant in human pathogenic 
organisms, there is a need to develop alternative antimicrobial drugs for the treatment 
of infectious diseases. One approach is to screen new, cheap and effective drugs from 
other sources, including plants, for possible antimicrobial properties that will be able 
to act for longer periods before resistance set in. In recent years, antimicrobial 
properties of medicinal plants have been reported from different parts of the world 
including Thailand, in which indigenous culture possess a rich heritage of healing 
with medicinal plants (Roengsumran et al., 1997; Ahmad and Beg, 2001; Brantner 
and Grein, 1994; Mehmood and Mohamad, 1998; Samy et al., 1999; Sokmen et al., 
1999). Previous study, Tor, Klara, Sigmund, Chun, Victoria, and Olaf (2003) found 
that marine organisms were a rich source for discovering antimicrobial and other 
bioactive compound such as flounder found that marine organisms were a rich source 
  
for discovering antimicrobial and other bioactive compound such as flounder 
(Pleuronectes platessa), saithe skin ( Pollachius virens) had antibacterial activity 
against Listonella anguillarum. The 6 novel AMPs (antimicrobial peptides) isolated 
from the coelomocytes was shown to have a  MIC of 1.2-5.0 µM against E. coli and S. 
aureus. Ara-A (acyclovir) and AZT (zidovudine) isolated from sponge were shown  
antiviral activity.  
              Thailand, there are many medicinal plants which have antiseptic properties 
and are used for antimicrobial activity including Zingiberaceae family such
as Alpinia galanga (A. galanga), Alpinia nigra (A. nigra) and Alpinia officinarum (A. 
officinarum) which have some chemicals of flavonoids such as galangin. Some 
flavonoids such as baicalin can affect synergy with β-lactam antibiotics for anti-
MRSA and penicillin-resistant Staphylococcus aureus (Lui et al., 2000). Previously 
antibacterial studies found that galangin has an effect on anti-MRSA when combined 
with β-lactam antibiotic drugs (Griangsak Eumkeb and Richards, 2003).  
              Maharat Nakhon Ratchasima hospital is the largest hospital in Nakhon 
Ratchasima province, northeast of Thailand. The problem of drug-resistant bacteria in 
many sections of the hospital has been previously reported such as MRSA, CREsC 
and CREnC (Maharat Nakhon Ratchasima hospital, 2001).                       
              However, there are no researchers investigate about the used of galangin, 
baicalein, apigenin, luteolin and quercetin alone and in combination with β-lactam 
antibiotics to treat MRSA and CREnC. These bacteria have had drug-resistance in 
high level in many sections of Maharat Nakhon Ratchasima hospital and other 
hospitals in Thailand and world wide (Jungthirpanich, Tungsathapornpong and  
  
Chaumrattanakul, 2000; Kusum and Dejsirilert, 2003; Nakhon Ratchasima hospital, 
2001; National Nosocomial Infection Surveillance, 2000). 
1.1 Objectives of Study 
              1.1.1 To test the effectiveness of selected flavonoids (apigenin, baicalein, 
galangin, luteolin or quercetin) whether they take effect on β-lactam antibiotic 
resistant bacteria. 
              1.1.2 To test the effectiveness of selected flavonoids (apigenin, baicalein, 
galangin, luteolin or quercetin) when combined with β-lactam antibiotics whether 
they take affect on β-lactam antibiotic resistant bacteria. 
              1.1.3 To investigate the mechanism of action of selected flavonoids on β-
lactam antibiotics resistant bacteria when use singly and in combination with β-lactam 
antibiotics by examining morphology with transmission electronmicroscopy (TEM),  
capillary electrophoresis and enzyme assay. 
 
1.2 Research hypothesis 
              1.2.1 Apigenin, baicalein, galangin, luteolin or quercetin could show 
antibacterial activities against clinical isolates of methicillin-resistant S. aureus 
(MRSA), ceftazidime-resistant E. cloacae (CREnC) and ampicillin-sensitive E. 
cloacae (ASEnC). 
                1.2.2 Apigenin, baicalein, galangin, luteolin or quercetin in combination 
with β-lactam antibiotics could show antibacterial activities against clinical isolates of 
MRSA, CREnC, and ASEnC. 
 
  
1.3 Scope and limitation of the study 
               1.3.1 Bacterial suspension standard curves for clinical isolates of MRSA, 
CREnC and ASEnC were done. 
               1.3.2 Minimal inhibitory concentrations (MICs) of cloxacillin, ampicillin,  
ceftazidime and the flavonoids were done for clinical isolates of MRSA, CREnC, and 
ASEnC. 
               1.3.3 Checkerboard assay of these combinations that show the lowest MIC 
were selected to do further investigations such as viable counts, TEM and 
electrophoresis.     
 
1.4 Expected results 
              1.4.1 Some selected flavonoids could show antibacterial activity against β-
lactam antibiotic resistant bacteria. 
              1.4.2 Some selected flavonoids could show synergism activity against β-
lactam antibiotic resistant bacteria when combine with β-lactam antibiotics.   
              1.4.3 The preliminary informations of the mechanism of action of some 
flavonoids on β-lactam antibiotics resistant bacteria when they are used singly and in 
combination with β-lactam antibiotics by morphology examining with transmission 
electronmicroscopy (TEM), capillary electrophoresis and enzyme assay will be 
elucidated. 
              1.4.4 Providing additional scientific data on synergism antimicrobial activity 
between the combination of some flavonoids and β-lactam antibiotics. 
        
 
  
CHAPTER II 
LITERATURE REVIEWS 
                           
              The drug-resistant bacteria posses a serious world-wide problem that need 
immediately solution because it is harmful to human. Drug resistant microbial is an 
unavoid consequence of the utilization of antimicrobial agents in a given 
environment. Nowhere is the importance of resistance more evident than among 
agents of the β-lactam antibiotic family (Sanders and Sanders, 1992). 
              β-lactam antibiotics include penicillin, cephalosporins and related 
compounds, are active against many gram-positive, gram-negative and anaerobic 
organisms. Information based on "expert opinion" and antimicrobial susceptibility 
testing support certain antibiotic choices for the treatment of common infections, but 
less evidence-based literature is available to guide treatment decision. Evidence in the 
literature supports the selection of amoxicillin as first-line antibiotic therapy for acute 
otitis media. Alternative drugs, such as amoxicillin-clavulanate, trimethoprim-
sulfamethoxazole and cefuroxime axetil, can be used to treat resistant infections. 
Penicillin V remains the drug of choice for the treatment of pharyngitis caused by 
group A Streptococci. Inexpensive narrow-spectrum drugs such as amoxicillin or 
trimethoprim-sulfamethoxazole are first-line therapy for sinusitis. Animal and human 
bites can be treated most effectively with amoxicillin-clavulanate. For most outpatient 
procedures, amoxicillin is the preferred agent for bacterial endocarditis prophylaxis. 
β-lactam antibiotics are usually not the first choice for empiric outpatient treatment of 
  
community-acquired pneumonia. Based on the literature, the role of β-lactam 
antibiotics in the treatment of bronchitis, skin infections and urinary tract infections 
remains unclear (Keith and Edward, 2000). 
              β-lactam antibiotics, which are named for  the β-lactam ring in their chemical 
used structure, include the penicillin, cephalosporins and related compounds. These 
agents are active against many gram-positive, gram-negative and anaerobic 
organisms. The β-lactam antibiotics exert their effect by interfering with the structural 
crosslinking of peptidoglycans in bacterial cell walls. Because many of these drugs 
are well absorbed after oral administration, they are clinically used in the outpatient 
setting (Keith and Edward, 2000).  
              MRSA stands for methicillin resistant Staphylococcus aureus. It is a type of 
bacterium commonly found on the skin and/or in the nose of healthy people. Although 
it is usually harmless at these sites, it may occasionally get into the body (e.g., 
through breaks in the skin such as abrasions, cuts, wounds, surgical incisions or in 
dwelling cathesters) and cause infections. These infections may be mild (e.g., pimplea 
or boils) or serious (e.g., infection of the bloodstream, bones or joints). The treatment 
of infections due to Staphylococcus aureus was revolutionised in the 1940s by the 
introduction of the antibiotic penicillin. Unfortunately, most strains of Staphylococcus 
aureus are now resistant to penicillin. This is because Staphylococcus aureus has 
'learnt' to make substance called β-lactamase, that degrades penicillin, destroying its 
antibacterial activity. It is a bacterium that has developed a resistance to most 
antibiotics commonly used for Staphylococcus infection. These drugs include 
methicillin, oxacillin, nafcillin, imipenem and other β-lactams. MRSA can affect 
people in two different ways, colonization or infection. When the person carries the 
  
flora on the skin or in the nose without showing signs or symptoms of infection, the 
person is said to colonize. If a person has signs of infection that are caused by MRSA 
(such as abscesses, wound infection, pneumonia, respiratory infections, blood, stool 
or urinary tract infection), the person is said to be infected. MRSA most often spread 
from person to person by direct contact, for example, in medical setting. MRSA is 
most commonly spread from patient to patient by health care worker's hands (Barret 
et al., 1968; Chamber, 1997; http:// www. netdoctor.co.uk /diseases/ facts/mrsa.htm). 
 
2.1 Microorganisms 
     2.1.1 Bacterial structure 
 
 
                                     Figure 1 Show structure of bacterial cell 
                  (www. microbeworld.org/img/aboutmicro/bacteria/bactdiag.gif) 
 
              The cytoplasmic membranes of gram-positive and gram-negative bacteria are 
indistinguishable. Each is composed of protien, lipids, phospholipids and a small 
amount of carbohydrate. It acts as an osmotic barrier, synthesizes the cell wall and 
provides a site to implant the chromosome. The other important functions are serving 
  
as the site of selective permeability, cytochrome activity, carrier-mediated transport 
and generation of proton motive force (PMF). 
              The periplasm is the space between the inner and outer membrane of a gram-
negative bacterium, and the cell wall lies within it. The periplasm contains enzymes 
that hydrolyze large molecules, hydrolyze antibiotics, and binding protein that 
facilitate transport. 
              The cell wall is a web-like structure that is sometimes called the murien 
sacculus. It is composed of peptidoglycan. The cell wall provides the cell with its 
sharp and osmotic stability. The cell wall constituents are peptidoglycan, teichoic 
acids and lipoteichoic acids. 
              Only gram-negative bacteria have an outer membrane. Porins and porin-like 
protiens in the outer membrane allow the membrane to act as a molecular sieve, 
restricting the access of some molecules to the cell wall and periplasm. The most 
clinical significant component of the outer membrane is a phospholipid like molecule 
called lipopolysaccharide (LPS) (Walker, 1999). 
              
                    
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Comparison of the thick cell wall of gram-positive bacteria with the 
comparatively thin cell wall of gram-negative bacteria. Note the complexity of the 
gram-negative cell envelope (outer membrane, its hydrophobic lipoprotein anchor; 
periplasmic space).                                                      
              (www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.figgrp.294) 
       
      
 
  
     2.1.2 Bacteria types 
         2.1.2.1 Staphylococcus aureus (S. aureus) 
           Family: Micrococcaceae 
           General characteristics: 
              The S. aureus is gram-positive cocci. It is a spherical cell (0.5 to 1.5 μm) 
that appears singly, in pairs, and in irregular clusters. This organism is non-motile, 
non-spore forming, facultative anaerobe and chemoorganotrope (both respiratory and 
fermentative metabolism). Colonies appear creamy, white or light gold and sometimes 
yellow to orange. The optimum temperature for S. aureus is 30-37ºC (Holt, Krieg,  
Sneath, Staley, and Williams, 1974, 1994). 
 
           Clinical significance: 
              S. aureus is responsible for a wide variety of infections and disease due to 
toxins. Infections caused by S. aureus are supparative and pyogenic. Some of the 
common skin infections are boils, carbuncles, folicullitis and bullous impetigo. These 
opportunistic infections occur usually as a result of previous skin injuries (Mahon and 
Manuselis, 2000; Shimeld and Rodgers, 1999). 
 
           Antibiotic susceptibility characteristics: 
              Penicillin became more widely available and used. By the year 1950, isolated 
strain of S. aureus was resistant to penicillin by producing an enzyme that cleaves its 
β-lactam ring. The penicillinase-resistant penicillins, which were nafcillin, methicillin 
and oxacillin, were used to treat the more resistant isolates. The 1970s, resistance 
developed to these compounds. The MRSA have become a costly problem in 
  
hospitals. The rest anti-infective therapy against MRSA is vancomycin (Shimeld and 
Rodgers, 1999). 
              Diseases associated with S. aureus are systemic infections (bacteremia, 
septicemia), toxin productions (food poisoning, scaled skin syndrome, toxic shock 
syndrome (TSS)) (Mahon and Manuselis, 2000; Shimeld and Rodgers, 1999).  
 
         2.1.2.2 Enterobacter cloacae (E. cloacae) 
              Family: Enterobacteriaceae 
              General characteristics: 
              E. cloacae is a gram-negative, straight rod (0.6-1.0 µm wide x1.2-3.0 µm 
long). It is facultative anaerobe and chemoorganotrop. The optimal temperature for E. 
cloacae is 30-37ºC. It widely distributed in nature and it can be found in the soil, 
dairy products, water and sewage. It may also be present in the intestinal tract of 
humans and animals (John et al., 1994; Shimeld and Rodgers, 1999). 
          
           Clinical significance 
              E. cloacae generally does not cause disease in healthy individuals but 
sigificantly cause the infections in immunocompromised or otherwise debilitated 
patient. This species is an opportunistic pathogen causing burn, wound and urinary 
tract infection and occasionally septicemia and meningitis (Mahon and Manuselis, 
2000).  
 
 
 
  
           Antibiotic susceptibility characteristics 
              Most isolates of Enterobacter are resistant to ampicillin and first-generation 
cephalosporins. Second- and third-generation cephalosporins may be effective 
(Shimeld and Rodgers, 1999).  
      
2.2 Antibiotics  
              Antibiotics are chemical substances produced from various microorganisms 
(bacterial and fungus) that kill or suppress the growth of other microorganisms. The 
term is also uses for synthetic antimicrobial agents such as sulfonamides and 
quinolones (Salerno, 1999). 
            
     2.2.1 Mechanisms of action of clinically used antimicrobial drugs                         
              Selective toxicity is a drug that harmful to a parasite without being harmful 
to the host. The mechanisms of action can be placed under four headings: 
              a) Inhibition of cell wall synthesis. 
              b) Inhibition of cell membrane function. 
              c) Inhibition of protein synthesis (i.e, inhibition of translation and    
                   transcription of genetic material). 
              d) Inhibition of nucleic acid synthesis (Brooks, Butel, Ornston, Jawetz, 
Melnick, and Aldelberg, 1995). 
 
           Antibiotics that inhibit bacterial cell wall synthesis                   
              The two most important classes of antibiotics that inhibit bacterial cell wall 
synthesis are β-lactam and glycopeptides. In this literature review describe only β- 
  
lactam that is one of antibiotic group associated with study (Page, Curtis, Sutter,  
Walker, and  Hoffman, 1997). 
 
     2.2.2 β-lactam   
              β-lactam antibiotics possess a four-member nitrogen-containing β-lactam 
ring. It interferes with bacterial cell wall synthesis by inhibiting the cross-linkage of 
the peptide side chains of the bacterial cell wall. β-lactams are mainly bactericidal and 
exhibit time-dependent killing (Page et al., 1997). 
 
           2.2.2.1 Penicillin They are a byproduct of Penicillium notatum. It consists of a 
β-lactam ring fused to a five-member, sulfur-containing thiazolidine ring. 
Modification of the side chain at position six of the β-lactam ring results in drugs with 
different antibacterial and pharmacological properties. There are four classes of 
penicillins, natural penicillins, antistaphylococcal penicillins, aminopenicillins and 
antipseudomonal penicillins (Page et al., 1997). 
 
           2.2.2.2 Cephalosporins The first cephalosporin was discovered from 
Cephalosporium acremonium. It consists of a β-lactam ring fused to a six-member 
sulfur-containing dihydrothiazine ring. Individual cephalosporins are created by side-
chain substitutions at position seven of the β-lactam ring and position three of the 
dihydrothiazine ring. Cephalosporins are traditionally classified into first-, second- 
and third-generation drugs based on their spectrum against aerobic gram-negative 
bacilli, which increases from first to third generation (Page et al., 1997). 
 
  
          Resistance to β-lactam antibiotics 
              Bacterial resistance against β-lactam antibiotics is increasing at a significant 
rate and become a common problem in primary care medicine. There are several 
mechanisms of antimicrobial resistance to β-lactam antibiotics. One important 
mechanism is the production of β-lactamase, which is enzyme that cleave the β-
lactam ring. β-lactamase activity can occur in gram-positive organisms 
(Staphylococcus aureus and Staphylococcus epidermidis); gram-negative organisms 
(Haemophilus influenzae, Neisseria gonorrhoeae, Moraxella [ formerly Branhamella] 
catarrhalis, Escherichia coli and Proteus, Serratia, Pseudomonas and Klebsiella 
species); anaerobic organisms (Bacteroides species). The newer β-lactam antibiotics 
can be highly effective in combating infections caused by β-lactamase producing 
organisms. When used alone, β-lactamase inhibitors (clavulanate, sulbactam and 
tazobactam) have weak intrinsic antibacterial activity, but their effectiveness increase 
when they are combined with β-lactam antibiotics (e.g., amoxicillin-clavulanate 
[Augmentin®]) (Keith and Edward, 2000). 
              Spectrum including gram-positive bacteria antibiotics, and some β-lactams 
have been developed which inhibit a range of gram-negative bacteria. It may be innate 
resistance to the original β-lactams including the outer membrane of the gram- 
negative cell wall or may be acquired resistance including β-lactam enzymes which 
may be acquired by resistance transfer (Katzung, 1998). 
 
           Antibiotic that inhibit bacterial deoxyribonucleic acid synthesis 
              Each year, more than 500 metric tons of chemotherapeutic agents of various 
types are manufactured and used. In 1994, 37% cephalosporins, 17% penicillins and 
  
14% quinolones are produced and used world wide (Madigan, Martinko, and Parken,   
2000).  
              Ceftazidime is a third generation cephalosporin that active against aerobic 
gram-negative bacilli particularly Enterobacteriaceae. Usual adult dose for this 
antibiotic is 200 mg every 12 h or 0.5-2 g every 8-12 h for intravenous (IV) (Salerno, 
1999). A cost per vial (1 g) of ceftazidime is about 400 baht. 
              Methicillin is a penicillinase resistant penicillin, which is the usual treatment 
for S. aureus. Over the past 30 years, most strains of S. aureus have become resistant  
to commonly used antibiotics. This makes infections caused by this organism more 
difficult and expensive to treat. Usual adult dose for the methicillin is 1 g every 4-6 h 
for intramuscular (IM) and 1 g every 6 h for IV (Salerno, 1999). 
              Cloxacillin is a semisynthetic antibiotic of the penicillin group that is used 
primarily to treat infections caused by Staphylococci, Streptococci, or Pneumococci. 
Cloxacillin is for use against Staphylococci that produce beta-lactamase. It is sold 
under a number of trade names, including Cloxapen ® and Orbenin ®. 
 
     2.2.3 Major groups of antimicrobial compounds from plants 
              Plants are rich in wide variety of secondary metabolites. Useful antimicrobial  
phytochemicals can be divided into several categories (Cowan, 1999; Kaufman, 
Cseke, Warben, Duke, and Brielmann, 1999). 
 
           Phenolics and polyphenols 
           2.2.3.1 Simple phenols and phenolic acid 
  
              Most of the simple phenols are monomeric components of the polymeric 
polyphenols and acid which make up plant tissue, including lignin, melanin, flavolin 
and tannins. The sites and number of hydroxyl groups on the phenol group are 
thought to be related to their relative toxicity to microorganisms, with evidence that 
increased hydroxylation results in increased toxicity. The mechanisms though to be 
responsible for phenolic toxicity to microorganisms including enzyme inhibition by 
the oxidized compounds, possibly through reaction with sulfhydryl groups or through 
more nonspecific interactions with the proteins.  
              Phenolic compound possessing a C3 side chain at a lower level of oxidation, 
containing no oxygen are classified as oils and often cited as antimicrobial as well 
(Cowan, 1999; Kaufman et al., 1999). 
 
           2.2.3.2 Flavones, flavonoids and flavonols  
              Flavones are phenolic structures containing one carbonyl group. The 
flavonoids have two benzene rings separated by a propane unit and are derived from  
flavone. Flavonoids are group of naturally occuring compounds which are widely 
distributed in nature and are ubiquitous in vegetables, berries and fruits.  
              Flavonoids are polyphenolic compounds that are present in plants. 
Flavonoids comprise the most common group of plant polyphenols and provide much 
of the flavor and color to fruits and vegetable.  They have been shown to posses a 
variety of biological activity at non-toxic concentrations in organism (Heo et al., 
2001).  
               Heijnen and co-workers (2000) have reported that flavonoids effeciently 
protect against peroxynitrite toxicity. Two pharmacophores have been identified in 
  
flavonoids, namely the catechol group in ring B and the hydroxyl (OH) group at the 3-
positoin. Cowan (1999) and Kaufman et al. (1999) examined the structure-activity 
relationship. It was found that catechol (1, 2-dihydroxybenzene) is a potent 
peroxynitrite scavenger, whereas phenol (hydroxybenzene) is not (Cowan, 1999; 
Kaufman et al., 1999).  
 
2.3 Resistance to antibacterial agents (antibiotics) 
     2.3.1 Spectrum of activity of an antibiotic 
              The spectrum of activity is the range of microbial species and strains which 
the antibiotic is effective against some species. Some strains naturally resist (innate 
resistance) due to structure and properties of the microbe which normally sensitive 
become resistant (acquired resistance). 
 
     2.3.2 Microbial resistance to antibiotics 
              Origins of resistance in a popular of microbes is mutation in chromosome 
which transfers resistant genes from one microbe to another via conjugation 
(involving plasmids) or transduction (involving bacteriophages). Multiplication and 
spread of resistant microbes are selectively enhanced by the use of antibiotics in 
patients.  
              Significances of resistance are limitation on the use of antibiotics and cost of 
developing new antibiotics.   
              A resistant organism is an organism that will not be inhibited or killed by  
antibacterial agents at concentrations of the drug achievable in the body after normal 
dosage (Mims, Playfair, Roitt, Wakelin, and Rosamund, 1998). 
  
2.4 The using β -lactam antibiotics 
     2.4.1 Ampicillin; Ampicillin sodium;  
             6-[D-α-aminophenylacetamido] penicillanic acid;  
             D (-) -α-aminobenzyllpenicillin 
 
 
 
                     
 
              Molecular formular: C16H18N3O4S.Na  
              Molecular weight: 371.4 
              Appearance: white or almost white powder 
               Solubility: soluble in water   
               Constituted solution:   
                        Completenness of solution: the solid dissolves completely 
                        Clarity of solution: clear 
                        Paticulate matter:  essentially free from particles 
(www.sandoz.com/site/en/business/ant_infectives/product_list/products/471122Ampi
Nasteril.sh) 
 
 
 
 
            
  
      2.4.2 Cloxacillin; Cloxacillin sodium 
 
 
 
 
 
 
                Molecular formular: C19H17N3O5S.Na.H2O  
                Molecular weight: 475.9 
                Appearance:  white or almost white, crystalline powder 
                Solubility: soluble in water   
                Appearance of solution: 
                           Completenness of solution: the solid dissolves completely 
                           Clarity of solution: clear 
                           Paticulate matter: essentially free from particles  
(www.sandoz.com/site/en/business/ant_infectives/product_list/products/471122Cloxa
Nasteril.sh) 
 
     2.4.3 Ceftazidime; 1-[[(6R, 7R)-7-[2-amino-4-thiazoly)            
              glyoxylamido] -2-carboxy-8-oxo-5-thai-1-azabicyclo-[4.2.0]                
              oct2-en-3-yl] methyl] pyridinium hydroxide inner salt                      
           
 
 
  
 
                
 
               
 
 
              Molecular formular: C22H22N6O7S2.5H2O  
              Molecular weight: 636.6 
              Appearance: white to almost white powder 
              Solubility: soluble in water   
              Appearance of solution: 
Completenness of solution: the solid dissolves completely 
                           Clarity of solution: clear 
                            Paticulate matter: essentially free from particles 
(www.sandoz.com/site/en/business/ant_infectives/product_list/products/471122Cefta
Nasteril.sh) 
            
2.5 Medicinal plants used 
              Extracts of various plant parts of Aerva persica has been tested for their 
antimicrobial activity against human pathogenic bacterial strains of Staphylococcus 
aureus and Salmonella typhi and plant pathogenic fungal species Macrophomina 
phaseolina. Aqueous and alcoholic extracts were tested against all the 
microorganisms. All the plant parts showed antibacterial and/or antifungal activity 
(Gehlot and Bohra, 1998).  
  
              The resistance inhibitory activities of fifty-four mixtures (essential oil) from 
forty-one Korean aromatic herbs were tested against multi-drugs resistant 
Staphylococcus aureus SA2, which has resistances to ten usual antibiotics including 
chloramphenicol. As results, combinations of twenty-eight kinds of samples from 
twenty-one herbs and chloramphenicol have resistance inhibitory activities in dose 
dependent manner (Lee, Kim, Moon, and Shin, 1998). 
              With the therapeutic concept of using the defensive ability of plants against 
microbial infections, phytoalexin, an antimicrobial phytochemical was studied for its 
ability to inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA). 
Extracts from Sophola exigua (Leguminaceae) were fractionated by serial 
chromatography and the anti-MRSA activity of each fraction was determined by the 
agar-plate method. Among the activity isolates, 5, 7 ,2', 6'-tetrahydroxy-6-isoprenyl-8-
lavandulyl-4'-methoxyflavone (exiguaflavonone D) completely inhibited the growth 
of all the MRSA strains examined at the concentration of 1.56-6.25 μg/ml and 5, 2', 
6'-trihydroxy-8-lavandulyl-7-methoxyflavone (exiguaflavone B) inhibited at a 
concentration of 50 μg/ml. This former compound is accepted to be a 
phytotherapeutic agent for MRSA infection as an alternative to conventional 
antibiotics with unwanted side-effects or the appearance of antibiotic-resistant 
bacteria (Linuma et al., 1994). 
              Differently substituted flavanones were isolated from Leguminosae and their 
antibacterial activity was comparatively studied against methicillin-resistant 
Staphylococcus aureus (MRSA). The minimum inhibitory concentrations (MICs) of 
phytochemical flavones to clinical isolates of MRSA were determined by a serial agar 
dilution method. The structure-activity relationship has indicated that 2', 4'- or 2', 6'-
  
dihydroxylation of the B ring and 5, 7-dihydroxylation of the A ring in the flavone 
structure were important for significant anti-MRSA activity and that substitution with 
a certain aliphatic group at the 6- or 8-position also enhanced the activity. Among the 
thirteen flavanones tested, tetrahydroxyflavanones with these structural characteristics 
isolated from Sophora exigua and Echinosophora koreansis showed intensive activity 
to inhibit the growth of all MRSA strains at 3.13-6.25 μg/ml. The present 
hydroxyflavanones would be useful in the phytotherapeutic strategy against MRSA 
infections (Tsuchiya et al., 1996).  
 
           Potential uses of flavonoids 
              Most flavonoids have anti-inflammatory, anti-microbial activity, anti-
carcinogenicity properties, and are powerful antioxidants. Extracts from onion and 
various flavonoids induced the cellular antioxidant system. Onion extract and 
quercetin were able to increase the intracellular concentration of glutathione by 
approximately 50% (www.nal.usda.gov/fnic/foodcomp/Data/flav.html.).  
              Flavonoids are generally found in plants as their glycosides. Their activity is 
probably due to their ability to complex with extracellular and soluble proteins and to 
complex with bacterial cell walls. More phynolic flavonoids may also disrupt 
microbial membrane (www.nal.usda.gov/fnic/foodcomp/Data/Flov/flav.html). 
              Rhizomes of A. galanga, A. officinarum and, A. nigra contain volatile oil 
(0.5-1.0%), resin, galangol, kaempferide, galangin, alpinin and starch which roots and 
rhizomes are used for stomachace upset, indigestion, stomache and flatulence. They 
have not the effect on mutation and all both acute and chronic toxicity. So it is not 
danger to human (Smitinand, 2001; Temsirikul et al., 2001; Heo et al., 2001). Baicalin 
  
is a flavonoid which was extracted from edigible medicinal plant from China. It was 
called Xi-nan Huangqin (Scutellaria amoena C.H.Wright) that had effect combined 
with β-lactam antibiotics such as ampicillin, amoxycillin, benzylpenicillin, methicillin 
and cefotaxime for inhibiting methicillin-resistant S. aureus (MRSA) and penicillin -
resistant S. aureus (Liu, Durham, and Richards, 2000).                   
   
2.6 The using flavonoids 
     2.6.1 Apigenin; Versulin; 4′, 5-, 7-trihydroxyflavone; 5, 7- dihydroxy-2- 
               (4 hydroxyphenyl )-4H-1-benzopyran-4-one; 2-(ρ-hydroxyphenyl)-5, 7- 
              dihydroxychromone 
 
 
 
 
 
 
                        Molecular formula: C15 H10 O5 
                        Solubility: Soluble in hot alcohol and dimethylsulfoxide (DMSO).    
                                          Insoluble in water. 
                       Melting Point: 345-350°C 
                      Appearance: Yellow needle (Susan, 1996) 
 
              Apigenin is a flavonoid found in parsley, artichoke, basil, celery and other 
plants. Apigenin, a widely distributed plant flavonoid, was previously found to inhibit 
  
chemically induce ornithine decarboxylase (ODC) activity and skin tumor promotion 
and may be developed as a promising chemopreventive and/or chemotherapeutic 
 agent against prostate cancer (Birt, Mitchell, Gold, Pour, and Pinch, 2002; Gupta, 
Afaq, and Mukhtar, 2001).                                                   
              Apigenin strongly inhibited the bacterial mutagenesis induced by 
nitropyrenese. Apigenin protected against the cytotoxicity induced by 1-nitropyrene 
(1-NP) and 1, 6-dinitropyrene (1, 6-DNP) and gave a significant reduction of the 
frequency of sister chromatid exchange (Kuo, Lee, and Lin, 1992). 
              Oksus et al. (1984) found that the MIC for apigenin against Proteus vulgaris, 
Pseudomonas aeruginosa, Escherichia coli and Klebsiella pnemoniae ranged from 54 
to 219 µg/ml and that apigenin also proved to be active against the spore-former 
Bacillus subtilis. 
 
     2.6.2. Baicalein ; noroxylin; 5,6,7-trihydroxyflavone; 5,6,7-   
               trihydroxy-2-phenyl-4H-1-benzopyran-4-one 
 
                                                      
                               
                              
 
                         
 
                        Molecular formular: C15 H10 O5 
                        Solubility: Soluble in alcohol, methanol, ether, acetone, ethyl acetate,    
  
                                            hot gacial acetic acid and DMSO 
                         Melting Point: 264-265°C 
                        Appearance: Yellow needle and light yellow powder (Susan, 1996) 
 
              The dried roots of Scutellaria baicalensis (S. baicalensis) Georgi (common 
name: Huangqin in China) have been widely employed for many centuries in 
traditional Chinese herbal medicine as popular antibacterial and antivirus agents. It 
had effective against Staphylococci, cholera, dysentery, pneumococci and influenza 
virus. Baicalein, one of the major flavonoids contained in the dried roots, possesses a 
multitude of pharmacological activities (Huang, Tsang, Yao, and Chen, 2005).  
              Fujita et al. (2005) found that the effect of baicalein on the efflux of tetra 
cycline, using Escherichai coli KAM32/pTZ1252 carrying the tetK. Baicalein showed 
strong inhibition of transport of tetracycline with membrane vesicles prepared from 
Escherichai coli KAM32/pTZ1252.  
              Baicalein inhibited thrombin-induced product of plasminogen activator 
inhibition-1, and interluekin-1β-and tumor necrosis factor-α-induced expression in 
cultured human umbilical vein endothelial cells. The pharmacological findings had 
highlighted the therapeutic potentials of using plant-derived baicalein and its analogs 
for the treatment of arteriosclerosis and hypertension (Huang et al., 2005).  
              Baicalein halted enzymatic activity, adminished endothelial cell migration 
and differentation, and reduced anticancer response in several assays (Fung, 2003). 
              Kyoungho, Heasuk, Sang, Gyeong, and Wan (2003) found that baicalein 
selectively inhibited the nitric-oxide (NO) dependent apoptotic pathway of activated 
microglia by supreesing cytotoxic NO production. Also, the activation-induced cell 
  
death (AICD) inhibiting effects of baicalein were specific for inflammatory stimulus 
activated microglia.                                   
              Baicalein is a potent scavenger, attenuates oxidant stress during hypoxia, 
ischemia, reperfusion and mitochondrial ETC inhibiting and protects against cell 
death in an ischemia and reperfusion model (Zuo et al., 2002).                    
              The glycoside of baicalein is a potent anti-flammatory and anti-tumor agent. 
In the previous study, it was investigated the in vitro effects on the growth, viability 
and induction of apoptosis in several human prostate cancer cell lines (Chan et al., 
2000). 
              Schinazi et al. (1997) showed that baicalein inhibited certain viruses in vitro, 
including the Rauscher murine luekemia virus and the HIV virus, as well as cellular 
DNA polymerases, and that the inhibition of reverse transcriptase by the flavone 
baicalein was highly specific. These facts suggested that the flavone baicalein may be 
less toxic than the flavonols to the DNA and RNA polymerases in the host cell 
infected with retroviruses.  
              Platelet 12-lipoxygenase was inhibited by baicalein with an ID50 value of 
0.12 µg /mL, with minimal inhibition of platelet cyclooxygenase-1 (IC50 = 0.83mM) 
and baicalein inhibited lipid peroxydation, as assessed by production of TBARS, with 
an IC50 value of 5 µM. In addition to these effects, baicalein may play a role in 
apoptosis, as the compound inhibited cell growth of three human hepatocellular 
carcinoma celllines with IC50 values ranging from 17-70 µg /ml (Gao et al., 1996; 
Matsuzaki et al., 1996; Sekiya, and Okuda, 1996).  
 
      
  
     2.6.3 Galangin; norizalpinin; 3, 5, 7-trihydroxyflavone; 3, 5, 7- 
               trihydroxy-2-phenyl-4H-1-benzopyran-4-one  
 
 
 
 
 
 
                 Molecular formular: C15 H10 O5 
                 Solubility: Soluble in chloroform, benzene, ethanol, ether, and DMSO 
                 Melting point: 214-215°C 
                 Appearance: Yellowish needle (Susan, 1996) 
   
              Galangin, a number of the flavonol class of flavonoid, is presented high 
concentrations in medicinal plants (e.g., Alpinia officinarum) and propolis, a natural 
beehive product (Heo et al., 2001). Galangin is a flavonol that does not have any 
hydroxyl group in the B ring and has been suggested to be a substrate of cytochromes 
P450 which, through the hydroxyl of the B ring, could metabolise it to more 
genotoxic products. Galangin was more often acknowledged for its potential in cancer 
chemoprevention. And relatively nontoxic antioxidant and free radical scavenger that 
was capable of enzyme modulation demonstrates proapoptosis in leukemic cell lines 
and suppresses chemical genotoxicity (Duarte et al., 1997). 
               Tim and Andrew (2005) clearly demonstrates that galangin causes a 
significant increase in potassium loss from S. aureus cells, which may be attributed to 
  
either direct damage to the cytoplasmic membrane or indirect damage effected 
through autolysis/weakening of the cell way and consequent osmoticlysis. The MIC 
of galangin against multiple-resistant Staphylococcus aureus, Enterococcus spp. and 
Pseudomonas aeruginosa strains was significantly lower 0.16 to 0.44 mg/ml 
(Pepeljnjak and Kosalec, 2004).                          
              The MIC of galangin against Pseudomonas aeruginosa strains was present at 
0.17 ± 0.05 mg/ml. (Stjepan et al., 2004). Galangin was shown to have a minimum 
inhibitory concentration (MIC) of 25 to 50 µg/ml against all six strains of 
Staphylococcus aureus (S. aureus) that it caused a 100,000-fold decreasing in the 
viability of growing population of  S. aureus NCTC 6571 within the frist two hours of 
treatment. Decreases in viability of S. aureus NCTC 11561 and NCIMB 9968 
populations were also observed (Gushnie et al., 2003). 
              A combination of galangin or 3, 5, 7-trihydroxyflavone with vancomycin 
may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus 
faecium to the level of vancomycin-sensitive strains. Minimum inhibitory 
concentrations (MICs) of vancomycin against 67% of resistant clinical isolates and a 
type strain of Enterococci were lowered from > 250 μg/ml to 4 μg/ml in the presence 
of galangin (12.5 μg/ml) or 3, 5, 7-trihydroxyflavone (6.25 μg/ml). This combination 
action in reversing vancomycin resistance of Enterococci highlights novel drug 
targets has importance in the design of new therapeutic regimes against resistant 
pathogens (Lui et al., 2001). 
              Evaluation of the antibacterial activity of the galangin against ten randomly 
selected bacteria indicated sinificant activity against all the gram-positive bacteria 
tested with the minimum inhibitory concentration (MIC) ranging from 0.1 to 0.5 
  
mg/ml, and against Enterobacter cloacae which was significantly inhibited at an  
MIC of 0.1 mg/ml. Galangin indicated considerable activity against the fungi tested  
appeared to be particularly susceptible at a concentration of 0.01 mg/ml (Afolayan  
and Meyer, 1997 ). 
              The major antimicrobial compound isolated from the shoots of Helichrysum 
aureonitens plant in South Africa was found that it was able to inhibit some gram-
positive bacteria such as Bacillus cereus, Bacillus, pumilus and Staphylococcus 
aureus in the minimal inhibitory concentration (MIC) at 0.1-0.5 mg/ml but was not 
able to inhibit gram-negative bacteria except Enterobacter cloacae in the MIC at 0.1 
mg/ml. It had affected antifungal activity at 0.01mg/ml concentration (Afolayan, and 
Meyer,1997). Furthermore, galangin could affect to herpes simplex virus type I 
(HSVI), Coxsackie B virus type I (Cox.B1) at 12.47  µg/ml but least effected to 
retrovirus and no effect to adenovirus type 31 (Ad.31) (Meyer et al., 1997).  
               Galangin may be used for cancer chemoprevention because it could be 
synergetic with enzyme and suppressing genotoxicity of chemical (Heo et al., 2001). 
Cipak and other researchers (2003) found that galangin combined with cisplatin could 
eradicate cell toxicity in L 1210 murine leukemia cells. This may treat cancer in 
cooperation with cisplatin. Researchers found that galangin (with 3, 5, 7 OH-group 
position) could reduce toxicity of peroxynitrite because it has catechol at ring B or 
OH-group at 3, 5, 7 position (Heijnen et al., 2001).  
              Twelve clinical isolates of resistance Staphylococcus aureus (S. aureus) and 
four isolates of methicillin-resistance S. aureus were inhibited when treated with 
amoxicillin plus galangin 12.5 μg/ml. Furthermore, six clinical isolates of 
  
ceftazidime-resistant S. aureus had theirs resitance to ceftazidime by galangin at 
MICs 25 μg/ml to < 0.25 μg/ml (Graingsak Eumkeb and Richards, 2003). 
 
     2.6.4 Luteolin; digitoflavone; 3′, 4′, 5, 7-tetrahydroxyflavone; 2- 
               (3, 4-dihydroxyphenyl)-5, 7-dihydroxy-4H-1-benzopyran-4-one 
 
 
                        Molecular formular: C15 H10 O6 
                        Melting point: 328-330°C 
                        Solubility:  Soluble in ethyl acetate, formic acid, water, alkaline, and  
                                              DMSO   
                        Appearance: Yellow needle (Susan, 1996)  
  
              Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary 
intake. It exhibits a wide spectrum of pharmacological properties, but little is known 
about its biochemical targets other than the fact that it induces topoisomerase II-
mediated apoptosis. One study, showed that luteolin completely inhibits the catalytic 
activity of eukaryotic DNA topoisomerase I at a concentration of 40 μM, with an 
IC50 of 5 μM and further study supported its therapeutic potential as a lead anti-
cancer compound (Chowdhury et al., 2002).  
  
              Luteolin could inhibit Neisseria gonorrhoeae and Helicobacter pylori N-
acetyltransferase (NAT) activity and their growth (Chung et al., 2001; Tsou et al., 
2001). 
 
     2.6.5 Quercetin; Quercitin; Quercetrin; meletin; sophoretin; 
              3, 3', 4', 5-7- pentahydroxyflavone; 2-(3,4-dihydroxyphe- 
              nyl)-3, 5, 7- trihydroxy-4H-1-benzopyran-4-one 
 
 
 
 
                     Molecular formular: C15 H10 O 
                                Melting point: 314°C 
                     Solubility: Soluble in glacial acetic acid, aqueous alkaline, alcohol,  
                                       water and DMSO 
                     Appearance: Yellow needle (Susan, 1996)  
 
              Quercetin belongs to a class of water-soluble plant pigments called flavonoid. 
Quercetin can be found in onions, apples, green tea and black tea. Smaller amounts 
  
are found in leafy green vegetables and beans. Quercetin is chemically related to a 
class of flavonoids called (pro) anthocyanins. 
              Quercetin acts as an antihistamine, antiinflammatory, antiallergic, antiviral 
properties. As antioxidant, it protects LDL cholesterol (the "bad" cholesterol) from 
becoming damage. A variety of evidence indicated that quercetin possesses potent 
antioxidant properties. Cardiologists believe that damage to LDL cholesterol is an 
underlying cause of heart disease. Quercetin blocks an enzyme that leads to 
accumulation of sorbital, which has been linked to nerve, eye and kidney damage in 
those with diabetes. Quercetin is active against Bacillus cereus when present in the 
amount of 2.5 µg/ml (Wang et al., 1989).  
               Schinazi, Hughes, and Chen (1997) showed that quercetin inhibited certain 
viruses in vitro, including the Rauscher leukemia virus and HIV virus at nontoxic 
concentrations and quercetin was strong inhibitor of DNA polymerase-β.         
              Quercetin has been shown to cause chromosomal mutations in certain 
bacteria in test tube studied (Stoewsand, Anderson, Boyd, and Hrazdina, 1984).     
              Quercetin significantly reduced superoxide dismutase activity and increase 
the malonaldehyde content in SV40-transformed cell line (BNL SV A.8) cells. These 
are thought to be closely related to quercetin-mediated apoptosis. Young et al. (2004) 
suggested that quercetin was a dietary flavonoid that is capable of inducing selective 
growth inhibition and apoptosis in hepatic tumor cells. Flavone, quercetin is effective 
inhibiting the growth of the organisms. The most active extracts were white birch 
(Betula pubescens Ehrh.), pine (Pinus sylvestris L.) and potato (Solanum tuberosum 
L.) against gram-positive Staphylococcus aureus (Rauha et al., 2000). The 
antibacterial activitiy of Rubus ulmifolius extracts and some isolated constituents, 
  
quercetin-3-O -beta-D- glucuronide showed a high antimicrobial activity (Panizzi et 
al., 2002). Quercetin, up to 100 μg/mL, had any significant activity on selected gram-
positive strains, gram-negative strains, and yeasts.  It effected on anti-HIV activity 
(80% inhibition at 40 μM), which might depend on the free hydroxyl in the C-3 
position, as suggested by the lack of activity of the 3-O-acylquercetines (Gatto et al., 
2002).  
              Oral treatment with quercetin protected ABD2F1/Jena mice significantly 
against intraperitoneal encephalomyocarditis, Col, Sk, MM, Men M, L and Mengo M 
virus infections.  Tumor necrosis factor (TNF) produced a dose-dependent inhibition 
of vesicular stomatitis virus (VSV), encephalomyocarditis (EMCV) and herpes 
simplex virus type I (HSV-I) replication in WISH cells. The antiviral activity of TNF 
against VSV and EMVC was greatly enhanced by combination with quercetin. 
Induction of 2, 5-oligo-adenylate (2-5A) synthetase by TNF was also enhanced by 
quercetin. Addition of polyclonal antibodies to human interferon (IFN)-beta 
completely blocked both enhancement of antiviral activity and 2-5A synthetase 
induction (Ohnishi and Bannai, 1993). An antifungal agent 3, 4-dihydroxybenzoic 
acid was formed by peroxidase (POX)-dependent oxidation of quercetin on browning 
of onion scales (Takahama and Hirota, 2000). 
              Apigenin and quercetin were effective in reducing DNA oxidative damage 
and inhibited to poisomerase-catalyzed DNA irregularities. Furthermore, galangin and 
quercetin also displayed antiviral including anti-HIV activity. It was found that the 
flavonols were more active than flavones against herpes simplex virus type 1 (Panizzi 
et al., 2002). The aqueous organic solvent extracts of the leaves of Begonia malbarica 
Lam (Begoniaceae) were also tested against human pathonic bacteria and fungal 
  
strains by the agar-well diffusion method. The aqueous extracts showed activity 
against the gram-negative bacteria. The chloroform and methanol extracts showed 
activity against all the tested bacteria. The study supported the claim of the usefulness 
of the plant in respiratory tract infections and also suggested its use in diarrhoea and 
skin diseases caused by pathogenic bacteria (Ramesh, Viswanathan, Sarawathy,  
Balakrishna, Brindha, and Lakshmanaperumalsamy, 2002).                                    
              In Thailand, there are many medicinal plants which have antiseptic 
properties, antimicrobial activity including Zingiberaceae family such as A. galanga, 
A. nigra and A. officinarum. These medicinal plants have some chemicals of 
flavonoids such as galangin and baicalin could affect synergy with β-lactam 
antibiotics agianst MRSA and penicillin-resistant Staphylococcus aureus (Lui et al., 
2000). Previously antibacterial studies found that galangin had inhibitory effect 
against MRSA strain when combined with β-lactam antibiotic drugs (Griangsak 
Eumkeb and Richards, 2003). 
   
2.7 Laboratory methods used for antimicrobial susceptibility      
        testing    
              The inhibitory activity of an antimicrobial agent is determined by dilution 
testing, which produces a quantitative result. The decision concerning which method 
to used is based on several factors including cost, ease of use, flexibility, and degree 
of automation (Swan and Manivannan, 2000).  
 
     2.7.1 Susceptibility test method 
           Dilution Testing: 
  
              Dilution susceptibility tests determine the minimal concentration of an 
antimicrobial agent needed to inhibit growth of the microorganism being tested. For 
most dilution tests, antimicrobial agents are tested at log 2 (two-fold) serial dilutions. 
The lowest concentration at which there is no visible growth is called the minimal 
inhibitory concentration (MIC) (Swan and Manivannan, 2000).  
 
     2.7.2 Mechanism 
              When two antimicrobial agents act simultaneously on a homogeneous  
microbial population, the effect may be one of following. 
              1. No interaction; The combined action is equivalent to the sum of the actions 
of each drug when used alone (FIC index > 0.5-4.0). 
              2. Synergism; The combined action is significantly greater than the sum of 
both effects (FIC index ≤ 0.5). 
              3. Antagonism; The combined action is less than that of more effective agent 
when used alone (FIC index >4.0) (American Society for Microbiology, 2004; John, 
2004; Odds, 2003).  
               The most popular method used to detect antimicrobial interaction is 
checkerboard or chessboard titration, in which two drugs are cross-titrated against 
each other (Sawan and Manivanna, 2000). After incubation, the isobologram is 
constructed by plotting the inhibition of growth observed at each drug concentration 
on an arithmetic scale. The line of additive joins the MICs of the individual drugs 
acting alone, a deviation of this line towards the axes of the graph suggests synerg; a 
deviation away from the axes is often taken to indicate antagonism, although in 
difference may also produce this result (Sawan and Manivannan, 2000).       
                                                                          CHAPTER III 
                         MATERIALS AND METHODS 
 
3.1 MATERIALS 
     3.1.1 Test organisms 
           Bacterial strains 
 
              Staphylococcus aureus (methicillin-resistant) and Enterobacter cloacae 
(ceftazidime-resistant) were obtained from Maharat Nakhon Ratchasima hospital,  
Nakhon Ratchasima province, Thailand.  
 
       3.1.1.1 Identification of isolates of methicillin-resistant Staphylococcus 
                       aureus (MRSA) and ceftazidime-resistant Enterobacter cloacae  
                       (CREnC) 
           Identification of MRSA 
              MRSA was identified by biochemical characteristic tests following Holt et 
al. (1974, 1994). The results obtained were a gram-positive spherical. Colonies on 
nutrient agar were opaque, creamy, mucoid and smooth with entire margin. Catalase 
coagulase and VP tests were positive. Oxidase test was negative. The bacteria could 
hydrolyse starch. Acids were produced from carbohydrates, namely mannose and 
lactose. Nitrate was reduced to nitrite (Table 1). In this results, the characteristics of 
MRSA were similar to biochemical characteristic tests of S. aureus by Holt et al. 
(1974, 1994).  
           Identification of CREnC 
              CREnC was identified by biochemical characteristic tests following Holt et 
al. (1974, 1994). The results obtained were a gram-negative straight rod. Colonies on 
nutrient agar were yellow and mucoid. Catalase and VP tests were positive. Idole 
production, oxidase and MR tests were negative. The bacteria could hydrolyse gelatin 
and starch. Acids were produced from many carbohydrates, namely arabinose, 
cellobiose, lactose, maltose, melibiose, mannose, rhamnose, raffinose, sucrose, 
trehalose and xylose (Table 1). In this results, the characteristics of CREnC were  
similar to biochemical characteristic tests of  E. cloacae  by Holt et al. (1974, 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Characteristic of isolates of methicillin-resistant S. aureus and ceftazidime- 
resistant E. cloacae from Maharat Nakhon Ratchasima hospital 
 
 
Biochemical Test Clinical isolates of  MRSA Clinical isolates of CREnC 
Gram reaction + - 
Coagulase test + ND 
Catalase test + + 
Oxidase test - - 
Starch hydrolysis + + 
Indole production ND - 
Gelatin liquefaction ND - 
MR test                     ND - 
VP test + + 
Mannose + + 
Maltose - + 
Sucrose - + 
Lactose + + 
 
Note:  + Positive reaction 
 - Negative reaction 
 ND = Not Determined    
 
 
           3.1.1.2 Preparation and maintenance of stock cultures 
              The clinical isolates of bacteria were inoculated on nutrient agar slopes and 
incubated overnight at 37°C. These cultures were stored in a refrigerator 4°C. Fresh 
slope cultures were prepared every 3-4 weeks (Griangsak Eumkeb, 1999). 
      
     3.1.2 β-lactam antibiotics 
              Cloxacillin, ceftazidime and ampicillin were obtained from Sigma, Glaxo, 
Welcome (distributor in Thailand). β-lactamases of S. aureus and E. cloacae were 
obtained from Sigma (Poole, England).  
 
     3.1.3 Culture media 
                      Iso-sensitest broth, agar and Mueller-Hinton nutrient broth, agar were  
obtained from Oxiod. Apigenin, baicalein, galangin, luteolin and quercetin were  
obtained from Indofine chemical (The Flavonoid Company, USA). 
                Approximate formula per liter of each medium was as following: 
 
           3.1.3.1 Nutrient agar   
                          HiMedia nutrient agar was used for preparation of stock cultures on 
agar slopes and the basic agar culture of bacterial cells for colony counting. 
                        The formula was:                                                                             
                                                                                                                                g/litre 
                                      Peptic digest of animal tissue                                                5.0                        
                                      Sodium chloride                                                                    5.0  
                                      Beef extract                                                                           1.5                    
  
                                      Yeast extract                                                                          1.5  
                                       Agar                                                                                      1.5  
                                       pH (at 25°C) 7.4 ± 0.2 
 
           3.1.3.2 Nutrient broth 
              Difco nutrient broth was used as the basic liquid culture medium for growing 
the overnight cultures. 
                                The formula was:                                    
                                                                                                                                g/litre 
                                      Beef extract                                                                          3.0  
                                      Peptone                                                                                 5.0  
                                      pH 6.8±0.2 
 
           3.1.3.3 Iso-sensitest broth 
              Oxoid Iso-sensitest broth was developed specifically for antimicrobial 
susceptibility testing. It was used in the investigations to determine the permeability 
of the cytoplasmic membrane (CM) and outer membrane (OM) and the effect of 
flavonoids on the cell structure of MRSA, CREnC and ASEnC.   
                            The formula was:                                   
                                                                                                                                g/litre 
                                    Hydrolysed casein                                                                11.0 
                                    Peptones                                                                                 3.0 
                                    Sodium chloride                                                                     2.0 
                                    Soluble starch                                                                          1.0 
  
                                                                                                                                g/litre 
                                    Disodium hydrogen phosphate                                                2.0 
                                    Sodium acetate                                                                       1.0  
                                    Magnesium glycerophosphate                                                 0.2 
                                    Calcium gluconate                                                                   0.1             
                                    Cobaltous sulphate                                                              0.001             
                                    Cupric sulphate                                                                    0.001 
                                    Zinc sulphate                                                                      0.001                       
                                    Ferrous sulphate                                                                 0.001  
                                    Manganous chloride                                                           0.002  
                        Menadione                                                                          0.001  
                        Cyanocobalamin                                                                 0.001  
                        L-cysteine hydrochloride                                                      0.02    
                                    L-trypophan                                                                          0.02  
                        Pyridoxine                                                                          0.003  
                        Pantothenate                                                                       0.003  
                        Nicotinamide                                                                      0.003  
                        Biotin                                                                                0.0003  
                        Thiamine                                                                         0.00004  
                        Adenine                                                                                0.01  
                        Gaunine                                                                                0.01  
                        Xanthine                                                                               0.01  
                                    Uracil                                                                                    0.01  
                        pH 7.4 ±0.2 
  
           3.1.3.4 Iso-sensitest agar  
              Oxiod Iso-sensitest agar was the medium used for determining the activity of 
the antibacterial agent by the able count method and for preparing the bacterial 
suspension standard curve by determining the absorbance and viable count for a series 
of suspensions. 
              The formula was:          
                                                                                                                                g/litre                        
                                     Hydrolysed casein                                                                11.0 
                                     Peptones                                                                                 3.0 
                                     Glucose                                                                                   2.0 
                                     Sodium chloride                                                                     3.0  
                                     Soluble starch                                                                         1.0 
                                     Disodium hydrogen phosphate                                               2.0                        
                                     Sodium acetate                                                                       1.0 
                                     Magnesium glycerophosphate                                                0.2 
                                     Calcium gluconate                                                              0.1                        
                                     Cobaltous sulphate                                                         0.001                        
                                     Cupric sulphate                                                               0.001                        
                                     Zinc sulphate                                                                  0.001 
                                     Ferrous sulphate                                                             0.001  
                                     Manganous chloride                                                       0.002 
                                     Menadione                                                                      0.001 
   
 
  
                                                                                                                    g/litre 
                        Cyanocobalamin                                                             0.001      
                         L-cysteine hydrochloride                                                  0.02          
                         L-trypophan                                                                      0.02       
                         Pyridoxine                                                                      0.003   
                         Pantothenate                                                                   0.003      
                         Nicotinamide                                                                  0.003      
                         Biotin                                                                            0.0003     
                         Thiamine                                                                         0.00004      
                         Adenine                                                                            0.01        
                         Gaunine                                                                            0.01         
                         Xanthine                                                                           0.01         
                                     Uracil                                                                                0.01 
                                     Agar                                                                                    8.0 
                                     pH 7.4±0.2  
 
           3.1.3.5 Mueller-Hinton broth (MHB) 
              Difco Mueller Hinton broth was the medium used for determining the 
antimicrobial susceptibility testing. 
                          The formula was:                                                                          
                                                                                                                                g/litre      
                                     Beef infusion solids                                                           4.0 
                                     Casien hydrolysate                                                         17.5                        
                                     Soluble starch                                                                    1.5 
  
                                      pH 7.4 ± 0.2 at 37ºC 
             Mueller-Hinton had been cation-adjusted that has had the correct 
concentrations of the divalent cations of Ca++ 20 mg/l and Mg++ 10 mg/l (MBH). 
                         All culture media were dissolved by water. 
 
           3.1.3.6 Mueller-Hinton agar 
              Difco Mueller Hinton agar was the medium used for determining the 
antimicrobial susceptibility testing. 
                          The formula was:                                                                          
                                                                                                                                g/litre      
                                       Agar                                                                                 17.0 
                                       Beef heart infusion                                                               2 
                                       Casien acid hydrolysate                                                   17.5 
                                       Solube starch                                                                     1.5 
                                       pH 7.3±0.2 at 25ºC 
 
     3.1.4 Chemicals  
              All chemicals used were laboratory grade otherwise specified. 
                   Dimethylsulfoxide (DMSO)                                                          AR grade 
                   Disodium tetraborate                                                                     Lab grade 
                   Sodium chloride                                                                             AR grade 
                   Sodium phosphate                                                                         Lab grade 
                   Sodium hydroxide                                                                         Lab grade 
                   95% Ethanol                                                                                  Lab grade 
  
                    Amonium acetate                                                                          AR grade 
                    Acetronitrile                                                                                 Lab grade  
                    Albumin                                                                                        AR grade 
                    Lecithin                                                                                        Lab grade 
                    Tween 80                                                                                      Lab grade 
                    Paraformaldehyde                                                                         Lab grade 
                    Glutaraldehyde                                                                             Lab grade 
                    Osmiun tetroxide                                                                          Lab grade 
                    Methanol                                                                                      Lab grade 
                    Aradite                                                                                          Lab grade 
                    Agarose                                                                                         Lab grade 
                    Uranyl acetate                                                                               Lab grade 
                    Lead acetate                                                                                  Lab grade 
                    HEPES buffer                                                                               Lab grade 
                    Phosphate                                                                                     Lab grade 
                    PMSF                                                                                            Lab grade 
                    Triton X-100                                                                                 Lab grade   
                    Cloxacillin                                                                                     AR grade 
                    Ceftazidime                                                                                   AR grade 
                    Ampicillin                                                                                     AR grade 
                    Apigenin                                                                                        AR grade 
                    Baicalein                                                                                       AR grade 
                    Galangin                                                                                        AR grade         
                    Luteolin                                                                                         AR grade 
  
                    Quercetin                                                                                       AR grade 
                    β-lactamases                                                                                  AR grade    
                       
     3.1.5 Equipment 
3.1.5.1 Apparatus 
                  Whlimixer                                                                                   Labinco BV 
                   Spectronic 21                                                                              Milton Roy 
                  Labofuge 400R                                                                                  Heraeus 
                  Autoclave                                                                                           Yamato  
                  Laminar air flow                                                                              Woerden  
                  Hot air oven                                                                                        Shellab  
                  Shaking incubator                                                                                   Heto  
                  Hot plate                                                                              VELP scientifica 
                  Refrigerated Incubator                                                        VELP scientifica 
                  Ultramicrotome                                                                                       JEM                         
                  Micropipettors (2-20 μl)                                                                       Witeg 
                  Micropipettors (100-1000 μl)                                                               Witeg 
                  Cenrtifuge tubes                                                                                    Pyrex 
                  Spectraphysics                                                                                   Agilent 
 
           3.1.5.2 Glassware          
                 Beakers (50, 100, 250, 500, 1000 ml)                                                    Pyrex 
                 Pipettes (1, 5, 10 μl)                                                                              Brand                   
                 Measuring cylinder (10, 20 μl)                                                              Brand 
  
                 Petri dishes                                                                                             Pyrex 
                 Test tubes                                                                                               Pyrex 
               
3.2 Methods  
     3.2.1 Preparation of test solution and inoculum 
              Antibiotic test solutions were prepared by dissolving cloxacillin, ceftazidime  
and ampicillin (1 mg/ml) in sterile water. Baicalein and other four flavonoids 
(apigenin, galangin, luteolin and quercetin (500 μg/ml)) were dissolved in DMSO 
solution and were diluted with sterile water with adjustment to give the required test 
concentrations. Test organisms were incubated in 20 ml Cation-adjusted Muller-
Hinton broth (CAMHB) for MRSA and Iso-sensitest broth for CREnC for 18 h at 37º 
C. The cell cultures were centrifuged at 4,000 r.p.m/min. The cell pelletes was washed 
with saline, recentrifuged and resuspended in saline. The cell concentrations were 
adjusted with saline to give 1012 CFU /ml using a predetermined calibration curve of 
absorbance at 500 nm against viable count (Richards and Xing, 1993). This cell 
suspension was diluted with double strength broth to 106 CFU/ml. Overdried CAMH   
agar plates for MRSA and Iso-sensitest agar plates for CREnC were used for 
determining CFU (Iain et al., 1999). 
          
     3.2.2 Bacterial suspension standard curve 
           To select bacterial suspensions with a known viable count the following steps  
were followed:   
              A separate loopful of each bacterium was used to inoculate in 100 ml of  
  
nutrient broth. The cultures were incubated at 37°C for 18 h. The bacterial cells were   
pelletted by centrifugation at 4,000 r.p.m. for 10 mins. The cells were washed twice 
by resuspending and centrifuging at 4,000 r.p.m/min for 5 mins in 10 ml of 0.9% 
NaCl. The cells were resuspended in 50 ml of sterile 0.9%NaCl. The cell suspensions 
were diluted so that 5-6 spectrophotometer readings could obtained over the 
absorbance range of approximately 0.05-0.25 at a wavelength of 500 nm. Viable 
counts for each absorbance reading were determined in triplicates using overdried 
agar plate counting method. (Griangsak Eumkeb, 1999; Richards, Gregory, and Xing, 
1993).  
 
      3.2.3 MICs determination 
              Conventional broth dilution tests were used when only a few strains of 
bacteria need to be tested or when an accurate MIC estimation was required. A series 
of two-fold dilutions of the antibiotic under study was prepared in a volume of a 
suitable broth medium and a standard inoculum of the test strain (commonly 100,000 
bacteria) was introduced into each tube. The test was incubated at 37ºC overnight and 
the end-point was read that concentration of antibiotic in which no turbidity can be 
seen. Uninoculated tubes containing broth plus antibiotic and broth alone act as 
sterility controls an antibiotic-free tube inoculated with the test organism serves to 
indicated that the organism is viable in case the end-point was missed (Greenwood, 
2000). 
              MICs was determined using a broth macrodilution method.The  sterile wire 
loop test organism from a slope culture was inoculated into nutrient broth and was 
incubated for 18 h at 37°C.  Then, preparation of a bacterial suspension, the density of 
  
the bacterial suspension in normal saline was adjusted to approximately 5x107 
CFU/ml by using the absorption of bacterial suspension viable count standard curve. 
The inoculum of 0.1 ml of standard of suspension (18 h culture) of each strain of the 
test bacteria was added to triplicate tubes containing 9.90 ml CAMHB for MRSA and 
Iso-sensitest broth for CREnC plus serial dilutions of the antibacterials, to give 
approximately 5x105 CFU/ml. Tubes of broth without antibacterials were used as the 
control for each of the test bacteria. Incubation was at 37ºC for 24 h. The MIC was 
defined as the lowest concentration of antibiotic at which there is no visible growth in 
the triplicate tubes (Griangsak Eumkeb, 1999).  
 
     3.2.4 Checkerboard determination 
           Antimicrobial combinations were selected for various reasons including 
minimize drug toxicity by using the lowest possible doses of two or more agents that 
have additive efficacies but independent toxicities, or to reduce the potential for 
development of resistance to one agent (Swan and Manivannan, 2000). 
              Checkerboard titrations are relatively simple to perform and allow the 
assessment synergy at 24 h only. Dilution of antimicrobial agents may reduce to 
concentrations tested to a level at which synergy cannot be detected (Griangsak 
Eumkeb, 1999; Lorian, 1991).          
              Checkerboard determinations in antimicrobial combinations were performed 
following the method of Sabath (1967) with slight modification (Griangsak Eumkeb, 
1999). Antibacterial agent “A” and antibacterial agent “B” were diluted to1/10 of 
their MICs along the ordinate and abcissa respectively. 
              An 18 h culture of each of the testbacteria was prepare. The test bacterial 
  
suspensions were adjusted to 5 Х 107 CFU/ml using the absorption of bacterial 
suspension from the previously determine standard curve. 0.1 ml of the bacterial 
suspension was added to a series of 9.9 ml CAMHB for MRSA and Iso-sensitest 
broth for CREnC, plus 10% serial dilutions of the antibacterial combinations, to give 
1x105 CFU/ml. Tubes of broth without antibacterials were used as the controls for 
each of the test bacteria. The culture was incubated for 24 h at 37ºC. The test was 
carried out in triplicate. MICs were determined for each antibacterial combination and 
the isobolograms were plotted. The calculation of the FIC (Minimum Inhibitory 
Concentration) index for each antibacterial combination was undertaken as follows: 
 
        
      FIC  =         Conc.of A in MIC of A+B   +   Conc.of B in MIC of A+B 
                               MIC of A alone                           MIC of B alone 
                          
                                    FIC (A+B)    ≤  0.5                    Synergy 
                                   FIC (A+B)    >  0.5-4.0               No interaction 
                                    FIC (A+B)    >  4.0                     Antagonism 
                (American Society for Microbiology, 2004; Johnson, 2004; Odds, 2003) 
 
     3.2.5 Killing curve determinations 
              Viable counts for the determination of killing curve was performed as 
previously described (Richards and Xing, 1993) using a culture medium volume of 
100 ml. Inocula of 5 Х 105 CFU/ml was exposed to the antibacterials either singly or 
in combination with galangin or other four flavonoids (apigenin, baicalein, luteolin 
  
and quercetin) at an incubation temperature of 37°C.  After contact time of 0, 0.5, 1, 
2, 4, 6 and 24 h, a 1 ml sample of each incubated mixture was inactivated by addition 
of nutrient broth (9 ml) containing 0.125% lecithin and 3% (v/v) Tween 80. 
Subsequent dilution plating on overdried MH agar plates for MRSA and Iso-sensitest 
agar plates for CREnC in quadruplicate and incubation at 37°C for 18 h was allowed 
counting of growing colonies. The lowest detectable limit for counting was 103 
CFU/ml. Positive controls were used containing similar cell and solvent 
concentrations (Iain et al., 2000). 
                
     3.2.6 Transmission electronmicroscopy (TEM) method 
           Preparation of cultures 
              To examine the effect of apigenin, baicalein, galangin, luteolin and quercetin 
on the cell structure of MRSA or CREnC the following mehtods were used. 
              MRSA or CREnC or ASEnC were incubated separately in 10 ml nutrient 
broth for 18 h at 37°C.  A 0.2 ml volume of 18 h culture was inoculated into a 250 ml 
conical flask containing 98 ml CAMHB for MRSA and Iso-sensitest broth for CREnC 
which was placed in a water bath shaking at 100 oscillations/min for 4 h at 37°C. The 
cells were then, washed two times by suspending and centrifuging at 4,000 r.p.m. for 
5 min in 0.9% NaCl. Volume of 10 ml of 5 Х 106 of CFU/ml in 0.9% NaCl, the 4 h 
log phase culture was inoculated into 250 ml conical flasks each containing 90 ml 
CAMHB for MRSA and Iso-sensitest broth plus galangin and/or other four flavonoids 
plus selected antibacterial to give approximately 5 Х 105 CUF/ml final concentration.  
A flask containing 90 ml CAMHB for MRSA and Iso-sensitest broth for CREnC 
without any antibiotics was used as the control. The log phase cultures together with 
  
the appropriate flavonoid plus antibacterial and log phase control cultures was 
incubated for 4 h shaking at 100 oscillations/min in a water bath at 37°C (Richards et 
al., 1993; Xing, 1994).  
              The E. cloacae cultures were centrifuged at 6,000 g for 15 min at 4°C, and 
the supernate was removed. The pellets were fixed in glutaraldehyde 8% v/v in 0.1 M 
phosphate buffer (pH 7.2) for 1 h at 4°C and then were in 4%v/v in 0.1 M phosphate 
buffer (pH 7.2) for 4 h at 4°C. After washing in the buffer the bacteria was suspension 
in osmium tetroxide (OsO4) (Emscope, Watford) 1% w/v for 1 h at room temperature. 
They were then washed three times by centrifugation and resuspension in distilled 
water. The final pellet were resuspended in a small volume of warm agarose 2% w/v, 
poured on to a glass slide and were allowed to cool. When set, small pieces of gel 
containing suspended bacteria were cut out and dehydrated through a grade series of 
ethanol solutions. After embedding in Aradite (Agar Scientific Ltd, Stansted, Essex) 
thin sections will be cut with a diamond knife on a RMC ultramicrotome model MTX, 
stained with uranyl acetate and lead citrate, and examined in a JEOL, JEM 2010 
electron microscope at 80-100 kV.  
              Log phase of S. aureus (MRSA) cultures in cubated for 4 h in the presence of 
the appropriate concentrations of flavonoid plus selected antibacterial was centrifuged 
(4,000 g, 15 min, 4°C) and the supernatants were removed. The cell pellets of MRSA 
were fixed for 12 h respectively at 4°C with 2% w/v paraformaldehyde plus 2.5% w/v 
glutaraldehyde in 0.1 M phosphate buffer pH 7.2 containing 2.5 mM MgCl2. After 
washing with buffer the fixed cells were suspended in 1% w/v OsO4 for 6 h for 
MRSA at 20°C. The specimen embeding sectioning, staining and examining were as  
described previously (Richards et al., 1993). 
  
     3.2.7 Capillary electrophoresis 
              To examine the effect of some flavonoids as previously described above on 
the outer membrane (OM) and peptidoglycan associated proteins of MRSA or CREnC  
the following methods were used.  
              MRSA or CREnC was incubated separately in 100 ml quantities nutrient 
broth for 18 h at 37°C.  An 8.0 ml volume of 18 h culture was inoculated into a 250 
ml conical flask containing 192 ml Iso-sensitest broth which was place in a water bath 
shaking at 100 oscillations/min for 4 h at 37°C. Volumes of 100 ml of the 4 h log 
phase culture were inoculated into 250 ml conical flasks each containing 100 ml Iso-
sensitest broth plus galangin and/or other four flavonoids plus selected antibacterial. 
A flask containing 100 ml Iso-sensitest broth without any antibacterials was used as 
the control. The log phase cultures together with the appropriate flavonoid plus 
antibacterial and log phase control culture was incubated for 4 h shaking at 100 
oscillations/min in a water bath at 37°C. The bacterial concentrations used at 1/2 MIC 
were as followed. Selected flavonoids and drugs were used singly or combination for 
clinical isolates of MRSA or CREnC (Richards et al., 1993; Xing, 1994).  
              A 200 ml of bacterial culture was harvested by centrifugation (15 min, 6,000 
g, 4°C) and washed twice with N-2- hydroxyethyl piperazine-N,-ethanesulphonic acid 
(HEPES) buffer (10 mM, pH 6.8). The bacteria were resuspended in 10 ml diluted 
water and disintegrated by sonication (3 Х 60s with a 30 s cooling period between 
each burst) at 4 °C. Unbroken cells were removed by centrifugation at 5,000 g, 4°C 
for 5 min and the pellet was discarded. A 1 ml 20% (w/v) sodium-N-lauroyl 
sarcosinate (Sarkosyl) was mixed with supernatant and incubated for 30 min at room 
temperature. A visible clearing of the envelope suspension was indicated 
  
solubilization of the cytoplasmic membrane (CM). The OM and peptidoglycan 
complex was recovered by centrifugation at 40,000 g for 60 min, washed twice in 
distilled water containing 2 mg/ml phenyl methyl sulphonyl fluoride (PMSF).  
              Then, the same precise weight (25 mg) of OM and peptidoglycan protein 
extract of each sample from MRSA or CREnC was resuspended in 0.5 ml of (distilled 
water + 2ml/ml PMSF). Therefore, the same quatity of OM and peptidoglycan extract 
of each sample (50 mg/ml) from MRSA or CREnC could be investigated. These 
extract proteins were then stored frozen at -70°C (Markwell, Hass, Bieber, and 
Tolbert, 1978; Richards and Xing, 1996; Williams and Gledhill, 1991). 
               Peptidoglycan-associated protein (PG) extract (0.25 ml) was mixed with 
0.5M sodium borate solution (pH 9, 0.2 ml) and internal standard albumin 50 μl (20 
μg/ml). Samples were then separated by capillary electrophoresis (CE). The column 
was given a 1-min flush with 0.1M sodium hydroxide (100 μl), a 1-min flush with 
methanol (100 μl), then a 1-min flush with running buffer (100 μl) by syringe and 
followed by 5 min running with buffer under high voltags to equilibrium. The sample 
was loaded over 10s and the electrophoresis was at 20 kilo voltages (kV). The column 
eluent was monitored for ultraviolet (UV) absorbance at a wavelength of 205 nm. 
              A volume of protein extract was mixed with a volume of sample buffer and 
incubated at 20°C for 10 min. Each protein extrac suspension was injected to identify 
the relative protein by CE. The protein peak having the same migration time in CE 
was regarded to be that same protein. 
              Quantification was performed by comparison of the peak areas of the 
individual compound relative to those of the appropriate internal standard. The 
  
reproducibility of the assay was determined by carring out five independent replicate 
determinations.  
                 The capillary electrophoresis (CE) system used for the experiments was the 
electropherograph from Agilent (Germany). The fused-silica capillary was 50 µm I.D. 
and had a total length of 64.5 cm and a separation length of 40 cm. The sample 
loading data was collected with Spectraphysics Agilent Technologies Model 4270 
integrator (Xing and Richards, 1996).  
          
     3.2.8 Enzyme assay 
              β-lactamases of Bacillus cereus (B. cereus) and E. cloacae were obtained 
from Sigma (Poole, England). Enzyme activities were adjusted to concentration 
sufficient to hydrolyse 50-60% substrate in 5 minute. Flavonoids were pre-incubated 
with enzyme in 50 mM sodium phosphate buffer (pH 7.0) at 37°C for 5 minutes prior 
to substrate addition. Time-course assays were carried out using methanol/acetic acid 
(100:1) as stopping reagent. The analyses of the remaining substrate were determined 
by reverse-phase HPLC using acetronitrile/ammonium acetate as a mobile phase 
(Reading and Farmer, 1983).        
              The concentration of ceftazidime, cloxacillin and ampicillin which reduced 
either the rate of substrate hydrolysis by 50% alternatively reduces loss of substrate 
by 50% after a given enzymation period was termed the I50 value of the inhibitor. I50 
values are not kinetic constants and depend entirely on the test conditions under 
which they were determined. Assays with pre-incubation were carried out by reacting 
enzyme with β-lactam antibiotics for a set time period and then adding the substrate to 
measure the residual enzyme activity. β-lactamase had been used at a concentration 
  
sufficient to hydrolyse 500 µg/ml of ceftazidime, cloxacillin and ampicillin within 5 
min. Enzyme activity and hence its inhibition was measured by following the 
decrease the U.V. maximum for β-lactam antibiotics which occurs on hydrolysis by β-
lactamase (O’Callaghan et al., 1968; Reading and Farmer, 1983).  
               High performance liquid chromatography (HPLC) provides a further 
technique which was used to measure to stability of an antibiotic to β-lactamase in the 
presence of an enzyme inhibitor. Reaction samples (100 µl) were injected at various 
times on to Waters Bio-Sil C18 HL 90-5s reverse phase column eluted at 1.5 ml/min 
with 50 mM sodium phosphate buffer (pH 7.0).The eluent was monitored at 214 nm 
(Reading and Farmer, 1983). 
          
 
                                         
 
 
 
 
 
 
 
 
 
 
 
                                         CHAPTER IV 
                                 RESULTS AND DISCUSSION 
 
4.1 Bacterial suspensions viable count absorption standard curve 
              The results of the bacterial suspensions viable count standard curve for 
methicillin-resistant S. aureus (MRSA), ceftazidime-resistant E. cloacae (CREnC) 
and ampicillin-sensitive E. cloacae (ASEnC) are shown in Figures 3 to 5. 
              Figures 3, 4, and 5 indicate that approximately 5Х1012 CFU/ml of clinical 
isolates of methicillin-resistant S. aureus, ceftazidime-resistant E. cloacae and 
ampicillin-sensitive E. cloacae have absorption at 500 nm of 0.14, 0.15, and 0.13 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                 
          
 
 
 
 
 
 
 
 
        Figure 3 Standard curves for suspension of methicillin-resistant Staphylococcus             
                         aureus (MRSA) 
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          Figure 4 Standard curves for suspensions of ceftazidime-resistant              
                         Enterobacter cloacae (CREnC) 
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   Figure 5 Standard curves for suspensions of ampicillin-sensitive Enterobacter                                  
                   cloacae (ASEnC) 
 
 
 
 
 
Y=4E+13x-2E+11 
R2=0.8843 
Absorption of bacterial suspension viable count standard curve 
of Ampicillin - sensitive Enterobacter cloacae 
1.00E+11
1.00E+12
1.00E+13
1.00E+14
0.05 0.1 0.15 0.2 0.25
Absorption at 500 nm
V
ia
bl
e 
co
un
t (
C
FU
/m
l)
4.2 MIC determination 
              In present study, several flavonoids such as galangin, apigenin, baicalein, 
quercetin, and luteolin and β-lactams such as methicillin, cloxacillin, and ceftazidime 
were tested against clinical isolates of methicillin-resistant S. aureus, ceftazidime-
resistant E. cloacae and ampicillin-sensitive E. cloacae. The MIC values of the 
flavonoids and β-lactams quantitatively assessed by macrobroth dilution method as 
described previously (Lui, Durham, and Richards, 2000). The MICs of five flavonoids 
and three β-lactams in the present study are summarized in Table 2. The results showed  
that some antibacterial activities against drug-resistant isolates of bacteria tested, both 
gram-positive and gram-negative bacteria. The MICs of ceftazidime, ampicillin and 
cloxacillin against clinical isolates of methicillin-resistant S. aureus were 50, 100, and > 
1,000 μg/ml respectively. The MICs of these drugs against clinical isolates of 
ceftazidime-resistant E. cloacae were > 1,000 μg/ml. The MICs of ampicillin, ceftazidime 
and cloxacillin against clinical isolates of ampicillin-sensitive E. cloacae were 5, 10, 100 
μg/ml respectively. While all of these bacteria showed resistance to all five flavonoids at 
MICs > 400 μg/ml. 
 
        Disscussion 
              From these results showed MIC values of the flavonoids and β-lactam 
antibiotics against clinical isolates of MRSA, CREnC and ASEnC. Ampicillin and 
ceftazidime alone showed that some antibacterial activities against clinical isolates of 
MRSA at MICs 100 and 50 μg/ml respectively. But CREnC showed MICs of  ampicillin, 
ceftazidime and cloxacillin alone at > 1000 μg/ml for all of three drugs. Ampicillin, 
ceftazidime and cloxacillin alone showed MICs at 5, 10, and 100 μg/ml respectively for 
ASEnC. All tested flavonoids alone showed MICs at > 400 μg/ml for MRSA, CREnC 
and ASEnC. These results showed that MRSA and CREnC were strong resistant to all 
tested antibacterial drugs and flavonoids. 
              The previously researcher reported the antibacterial activities of β-lactam 
antibiotics and flavonoids alone. Variation between the results reported by previous 
workers and this study could be due to differences in concentration of β-lactam 
antibiotics, flavonoids and strains of test microorganism. The β-lactam antibiotics did not 
inhibit gram-negative bacteria, CREnC but showed activities against gram-positive, 
MRSA and ampicillin-sensitive E. cloacae (ASEnC) bacteria (Youichi et al., 2003;    
 Griangsak Eumkeb and Richards, 2004). From this study, gram-negative drug-resistant 
bacteria were greater resistant to β-lactam antibiotics. These were likely to be the result 
of the difference in cell wall structure between gram-positive and gram-negative bacteria. 
The gram-negative has a multi-layered and complex structure. The outer membrane can 
act as a barrier to many environmental substances including antibiotics (Essawi and 
Srour, 2000). 
 
 
 
 
 
                    Table 2 Minimum inhibitory concentration (μg/ml) of  the following β-lactams   
               and flavonoids againsclinical isolates of MRSA, CREnC, and ASEnC 
 
Organisms Ampicillin Ceftazidime Cloxacillin Baicalein Apigenin Luteolin Quercetin 
MRSA 100 50 > 1000 > 400 > 400 > 400 > 400 
CREnC > 1000 > 1000 > 1000 > 400 > 400 > 400 > 400 
ASEnC 5 10 100 > 400 > 400 > 400 > 400 
 
*MIC presented as Geomean of 3 observations 
 
4.3 Checkerboard determination 
              Some flavonoids showed diverse combinative effects on sensitive of MRSA and 
CREnC to β-lactam antibiotics. MIC determination are shown in Tables 3-4. The 
synergistic activity for all combination of baicalein and all tested β-lactams against 
clinical isolates of MRSA (FIC ≤ 0.5). The MICs of ampicillin, cloxacillin and 
ceftazidime were reduced from 100, > 1000, and 50 μg/ml to 5, 5, and 5 μg/ml 
respectively when combined with baicalein 5 μg/ml against this strain. Luteolin 5 μg/ml 
can also reduce MICs of ampicillin, cloxacillin and ceftazidime against clinical isolates 
of MRSA to 50, 50, and 30 μg/ml respectively. 
              Figure 6 shows effectiveness of the combination between ampicillin plus 
baicalein at 5:5 μg/ml against MRSA, but ampicillin plus galangin at 50:5 μg/ml, 
ampicillin plus apigenin at 50:10 μg/ml and ampicillin plus luteolin at 50:5 μg/ml shows  
 lower antibacterial activities against MRSA. 
                Figure 7 shows effectiveness of the combination between cloxacillin plus 
baicalein at 5:5 μg/ml and cloxacillin plus luteolin at 50:50 μg/ml. Figure 8 shows 
antibacterial activities of the combination of ceftazidime plus galangin, ceftazidime plus 
baicalein, ceftazidime plus quercetin at 5:5 μg/ml. Whereas ceftazidime plus luteolin at 
30:5 μg/ml shows lower antibacterial activity.       
              The combination between apigenin and tested β-lactams against clinical isolates 
of CREnC are shown in Figures 9-11. Figures 9 shows antibacterial activities of 
ampicillin 30 μg/ml plus apigenin or luteolin 5 µg /ml. Figure 10 shows antibacterial 
activities of cloxacillin plus apigenin at 30:5 μg/ml by reducing the MICs of cloxacillin > 
1000 to 30 μg/ml against this strain. Figure 11 indicates the MICs of ceftazidime was 
reduced from > 1000 to 5 μg/ml with apigenin or luteolin at 5 μg/ml.  
 
         FICs Index 
              The FICs index of five flavonoids plus three β-lactams against clinical isolates 
of MRSA and CREnC are shown in Tables 3–4. Baicalein at a concentration  5 μg/ml 
when combined with ampicillin at 5 μg/ml against clinical isolates of MRSA had 
significantly reduced their MIC values and exhibited FICs index of 0.0625. Baicalein at a 
concentration  5 μg/ml when combined with cloxacillin at 5 μg/ml against clinical isolates 
of MRSA had significantly reduced their MIC values and exhibited FICs index of 0.0175. 
Baicalein or galangin or quercetin at a concentration 5 μg/ml when combined with 
ceftazidime at 5 μg/ml against clinical isolates of MRSA had significantly reduced their 
MIC values and exhibited FICs index of 0.1125. These results showed synergy effect 
(Table 3). 
                The FICs index of apigenin or luteolin at a concentration 5 μg/ml when 
combined with ceftazidime at 5 μg/ml against clinical isolates of CREnC had 
significantly reduced their MIC values and exhibited FICs index of 0.0175. These results 
showed synergy effect (Table 4). 
 
         Discussion 
              The lowest fractional inhibitory concentration (FIC) for ampicillin plus 
baicalein, cloxacillin plus baicalein, ceftazidime plus galangin, ceftazidime plus 
baicalein, and ceftazidime plus quercetin combinations were 0.0625, 0.0175, 0.1125, 
0.1125, and 0.1125 respectively for MRSA. The lowest FICs for ceftazidime plus 
apigenin or quercetin were 0.0175 for CREnC.  
              These results indicate a high level synergistic activities since values below 0.5 
are widely accepted as representing synergism between two antibacterials (American 
Society for Microbiology, 2004; Johnson, 2004; Odds, 2003;). 
               The clinical isolates strains of MRSA and CREnC also had theirs resistance to 
ampicillin, cloxacillin and ceftazidime. These MICs were reversed when any of these β-
lactams was combined with 5 μg/ml of baicalein, galangin or quercetin for MRSA and 
apigenin or luteolin for CREnC. 
                    
Table 3 Minimum inhibitory concentration (μg/ml)* of  β-lactams used alone and 
in combination with different concentrations (μg/ml) of the following flavonoids 
against methicillin-resistant S. aureus (MRSA) 
Combination of agents 
MIC of 
MRSA 
Approximate 
FIC index 
 
FIC index value 
 
 Ampicillin/Galangin 50:5 0.5125 No interaction 
 Ampicillin/Baicalein 5:5  0.0625 Synergy 
 Ampicillin/Apigenin 50:10 0.525 No interaction 
 Ampicillin/Luteolin 50:5   0.5125 No interaction 
 Ampicillin/Quercetin 
 Cloxacillin/Galangin 
> 50:50 
> 50:50 
> 0.175 
> 0.175 
Antagonism, Synergy, No interaction 
Antagonism, Synergy, No interaction 
 Cloxacillin/Baicalein 5:5 0.0175 Synergy 
 Cloxacillin/Apigenin 
 Cloxacillin/Luteolin 
> 50:50 
> 50:50 
> 0.175 
> 0.175 
Antagonism, Synergy, No interaction 
Antagonism, Synergy, No interaction 
 Cloxacillin/Quercetin 
 Ceftazidime/Apigenin 
> 50:50 
> 50:50 
> 0.175 
> 1.125 
Antagonism, Synergy, No interaction 
Antagonism, Synergy, No interaction 
  Ceftazidime/Luteolin 30:5 0.6125 No interaction 
 Ceftazidime/Galangin 5:5 0.1125 Synergy 
  Ceftazidime/Baicalein 5:5 0.1125 Synergy 
  Ceftazidime/Quercetin 5:5 0.1125 Synergy 
  
 
*MIC presented as Geomean of 3 observation 
Table 4 Minimum inhibitory concentration (μg/ml)* of β-lactams used alone and in       
combination with different concentrations (μg/ml) of the following flavonoids against  
ceftazidime-resistant E. cloacae (CREnC) 
Combination of agents 
MIC of 
   MRSA 
Approximat
e FIC index FIC index value 
  Ampicillin/Galangin 
  Ampicillin/Baicalein 
> 50:50 
> 50:50 
> 0.175 
> 0.175 
Antagonism, Synergy, No interaction 
Antagonism, Synergy, No interaction 
  Ampicillin/Quercetin 
  Ampicillin/Luteolin  
  Ampicillin/Apigenin 
> 50:50 
30:5 
30:5 
> 0.175 
0.0425 
0.0425 
  Antagonism, Synergy, No interaction 
Synergy 
Synergy 
  Cloxacillin/Galangin > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Cloxacillin/Baicalein > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Cloxacillin/Luteolin  > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Cloxacillin/Quercetin > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Cloxacillin/Apigenin 5:30 0.08 Synergy  
  Ceftazidime/Galangin > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Ceftazidime/Baicalein > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Ceftazidime/Quercetin  > 50:50 > 0.175 Antagonism, Synergy, No interaction 
  Ceftazidime/Apigenin 5:5 0.0175 Synergy 
  Ceftazidime/Luteolin 5:5 0.0175 Synergy 
 
*MIC presented as Geomean of 3 observation 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 6 Isobologram constructed from checkerboard MIC data showing antibacterial  
      combination of ampicillin plus tested flavonoids against clinical isolates of MRSA  
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      Figure 7 Isobologram constructed from checkerboard MIC data showing antibacterial  
    combination of cloxacillin plus tested flavonoids against clinical isolates of MRSA  
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    Figure 8  Isobologram constructed from checkerboard MIC data showing antibacterial  
    combination of ceftazidime plus tested flavonoids against clinical isolates of MRSA  
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   Figure 9 Isobologram constructed from checkerboard MIC data showing antibacterial     
   combination of ampicillin plus tested flavonoids against clinical isolates of CREnC   
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    Figure 10 Isobologram constructed from checkerboard MIC data showing antibacterial 
     combination of cloxacillin plus apigenin against clinical isolates of CREnC 
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    Figure 11 Isobologram constructed from checkerboard MIC data showing antibacterial 
    combination of ceftazidime plus tested flavonoids against clinical isolates of CREnC 
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              From this study, both MRSA and CREnC were found to high resistant to selected 
antibacterial drugs or flavonoids when use singly. Some flavonoids in combination with 
β-lactam antibiotics showed synergistic effects on clinical isolates MRSA or CREnC. 
The results showed synergistic activity for all combination of biacalein and all tested β-
lactams against clinical isolates of MRSA, but there were no synergism effect of baicalein 
and these drugs on clinical isolates of CREnC. These results were supported by ealier 
studies that S. aureus was the most easily inhibited of all the bacteria exposed to 
flavonoids (Grosvenor, Supriono and Gray, 1995). The greater resistance of gram-
negative bacteria to flavonoids had been reported previously (Essawi and Srour, 2000). 
These observations are likely to be the results of the differences in cell wall structure 
between gram-positive and gram-negative. The gram-negative has a multi-layered and 
complex structure, the outer membrane can act as a barrier to many environmental 
substances including antibiotics (Essawi and Srour, 2000). The results indicated that 
flavonoids not only have an activity of their own against β-lactam resistant 
Staphylococci, but also have the ability to reverse the resistance of Enterobacter bacteria. 
 
 
 
 
 
 
 
4.4 Viable counts 
              Sampling killing curves resulting from five flavonoids alone and in 
combination with three β-lactams against clinical isolates of MRSA and CREnC are 
presented in Figures 12, 13, and 14. The control showed no reduction in the counts of 
CFU from control inoculum. Figure 12 shows that the combination of baicalein (10 
μg/ml) with either cloxacillin or ampicillin (10 μg/ml) caused a reducing of 5 Х 105 
CFU/ml for clinical isolates of MRSA to 103 CFU/ml within 6 h. Figure 13 shows that 
galangin, baicalein and quercetin (10 μg/ml) combined with ceftazidime (10 μg/ml) 
reduced value count for clinical isolates of MRSA from 5x105 to 103 CFU/ml within 6 
h. Figure 14 shows similar decreases of clinical isolates of CREnC when used 
ceftazidime (10 μg/ml) in combination with either apigenin (10 μg/ml) or luteolin (10 
μg/ml). The viable count of clinical isolates of CREnC was reduced from 5x105 to 103 
CFU/ml within 6 h and throughout 24 h. 
 
       Discussion 
              Results of viable count determinations were consistent with those of the 
checkerboard tests. Figures 12-13, the results suggested that baicalein in combination 
with β-lactams (ampicillin, cloxacillin or ceftazidime) had synergistic activity against 
MRSA by enhancing β-lactam activity in the combination. These results are in 
substantial agreement with the results from checkerboard that galangin, baicalein or 
quercetin in combination with ceftazidime had synergistic activity against MRSA by 
reducing ceftazidime concentration from 50 μg/ml to 5 μg/ml in the combination. 
              In addition, the results in Figure 14 indicated that apigenin or luteolin in 
combination with ceftazidime had synergistic activity against CREnC by enhancing 
ceftazidime activity in the combination. The concentration of below 17 μg/ml has 
been regarded by Livemore (1993) as the breakpoint concentration of clinical 
susceptibility. 
               These results indicated that the synergistic effects of β-lactam/flavonoid 
combinations against S. aureus may arise from contributions of three distinct types of 
activities. The first of these due to a weak/moderate direct antibacterial action of 
flavonoid on cell growth. The second mechanism arises from the ability of flavonoid 
to inhibit the β-lactamase hydrolysis of susceptible β-lactam antibiotics and hence 
restore cell sensitivity to the β-lactam antibiotics. The third mechanism involves an 
action against MRSA or CREnC, which is not dependent upon β-lactamase inhibition, 
but may be associated with the inhibitory interactions between β-lactams and 
penicillin binding protein (Iain et al., 2000).              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 Figure 12 The effect of cloxacillin or ampicillin combined with baicalein on the      
viable counts of  MRSA; ●, control (bacterial culture with corresponding solvent); ○, 
cloxacillin 50 μg/ml; ▼, ampicillin 50 μg/ml; Δ, baicalein 50 μg/ml; ■ , cloxacillin      
10 μg/ml plus baicalein 10 μg/ml; □, ampicillin 10 μg/ml plus baicalein 10 μg/ml;     
the values plotted are the means of 4 observations and the vertical bars indicate the  
standard errors of the means.  
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 Figure 13 The effect of ceftazidime combined with selected flavonoids on the viable 
counts of  MRSA.  ●, control (bacterial culture with corresponding solvent) 
;○ ,  ceftazidime 30 μg/ml; ▼ , quercetin 50 μg/ml; Δ ,  galangin 50 μg/ml; 
■ ,  baicalein 50 μg/ml; □ ,  ceftazidime 10 μg/ml plus galangin 10 μg/ml; 
♦, ceftazidime 10 μg/ml plus baicalein 10 μg/ml; ◊, ceftazidime 10 μg/ml 
plus quercetin 10 μg/ml; the values plotted are the means of 4 observations and the 
vertical bars indicate the standard errors of the means. 
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Figure 14 The effect of ceftazidime combined with selected flavonoids on the  
viable counts of CREnC. ●, control (bacterial culture with corresponding solvent); 
○, ceftazidime 30 μg/ml; ▼, apigenin 50 μg/ml; Δ, luteolin 50 μg/ml;■, ceftazidime    
10 μg/ml plus luteolin 10 μg/ml;  , ceftazidime 10 μg/ml plus apigenin 10 μg/ml;  
the values plotted are the means of 4 observations and the vertical bars indicate the  
standard errors of the means.  
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4.5 Electronmicroscopy 
              Electronmicroscope investigations clearly showed the combination of β-
lactams with selected flavonoids caused damage to ultrastructures of MRSA and 
CREnC cells (Figures 15-32). 
              Figure 15 shows the apperance of normal log phase cells of clinical isolates 
of MRSA. The cell wall and cytoplasmic membrane can be distingquished. The 
electron dense ribosomes can be scanned in the great number in cytoplasm. Figures 
16-18 show the effect of cloxacillin, ampicillin and ceftazidime respectively on 
clinical isolates of  MRSA strain. All tested antibiotics showed no activity against the 
clinical isolates of MRSA when used alone at 20 μg/ml.  
              Figure 16 shows the micrographs of log phase cells of clinical isolates of 
MRSA after exposure to cloxacillin 20 μg/ml. Some of the bacteria had a little larger 
than those of the control cells in Figure 15.  
              Figure 17 shows the micrographs of log phase cells of clinical isolates of 
MRSA after treatment with ampicillin 20 μg/ml. The micrographs showed that some 
of the bacteria had slightly larger gap between the cytoplasmic membrane and cell 
wall. Figure 18 shows the micrographs of log phase cells of clinical isolates of MRSA 
after expossure to ceftazidime at 20 μg/ml. Several cells of bacteria had rather larger 
gap between the cytoplasmic membrane and cell wall. 
              Figures 19-21 show the effect of selected flavonoids use singly on the MRSA 
cells which had been grown in Cation-adjusted Mueller-Hinton broth. Figure 19 
shows the micrographs of log phase cells of clinical isolates of MRSA after treatment 
with baicalein at 20 μg/ml. The baicalein treated cells were slightly bigger than the  
normal MRSA cells. Several cells of bacteria had ratherlarger gap between the  
                                                           
 cytoplasmic membrane and cell wall. Figure 20 shows thw micrographs of log phase
cells of clinical isolates of MRSA after treatment to galangin at 20 μg/ml. The 
bacterial cells showed no observable morphological cell damage but a few cells had 
slightly larger shape than normal cells. Figure 21 shows the MRSA cells after 
treatment with 20 μg/ml quercetin. The cells were approximately the same as control 
cells. 
              Figure 22-26 show the effect of selected flavonoids plus β-lactams antibiotics 
on clinical isolates of MRSA. Figure 22 shows the effect of the combination of 
ampicillin 10 μg/ml plus baicalein 10 μg/ml on clinical isolates of MRSA. Most of 
these bacteria exhibited cell wall and cell shape morphological damage. Many cells 
lost ribosome, consequently had big hole in cytoplasm. Figure 23 shows the 
micrographs of log phase cell of clinical isolates of MRSA after exposure to 
cloxacillin plus baicalein at 10:10 μg/ml.  A majority of these bacteria exhibited 
electron-transparent areas devoid of ribosomes (holes) clearly visible within the 
cytoplasm. A lot of cells lost some organells from cytoplasm such as chromosomes 
etc. Some of these cells showed considerably longer than normal cells. Figure 24 
shows the effect of the combination of ceftazidime plus baicalein at 10:10 μg/ml on 
clinical isolates of MRSA. These bacteria precisely exhibited morphological damage 
of cell wall, cytoplasmic membrane and lost of some organells from cytoplasm. 
Figure 25 indicate the micrographs of log phase cells of clinical isolates of MRSA 
after treatment with ceftazidime 10 μg/ml plus galangin 10 μg/ml. Some of these 
bacteria exhibited cell wall damage. Also electron-transparent area devoid of 
ribosomes and lost of some organells from cytoplasm. Figure 26 shows the 
                                                           
micrographs of log phase cells of clinical isolates of MRSA after treatment with 10 
μg/ml ceftazidime plus 10 μg/ml quercetin. Most of these bacterial cells showed very 
larger gap between cytoplasmic membrane and cell wall. Several bacterial cells  
clearly  exhibitedelectron-transparent area in cytoplasm due to lost most of organells. 
              Figures 27-32 show the effects of ceftazidime and/or selected flavonoids on  
log phase cells of clinical isolates of CREnC. Figure 27 shows the micrographs of 
normal log phase cells of clinical isolates of CREnC. The outer membrane and 
cytoplasmic membrane can be distinquised. The electron dense ribosomes can be 
observed in numerous numbers in cytoplasm. Figure 28 indicates the micrographs of 
log phase cells of clinical isolates of CREnC after treatment with ceftazidime at 20 
μg/ml. Some of these bacterial cells exhibited larger gap between outer membrane 
and cytoplasmic membrane in a few area of the cells. 
              Figures 29 and 30 show the micrographs of log phase cells of clinical isolates 
of CREnC after exposure to either luteolin or apigenin at 20 μg/ml respectively. These 
micrographs showed no observable morphological damage and were precisely the 
same as control cells. Figure 31 indicates the effect of the combination of ceftazidime 
plus luteolin at 10:10 μg/ml on clinical isolates of CREnC. Most of these bacterial 
cells obviously exhibited morphological cell wall and cell shape damage. A lot of 
bacterial cells clearly exhibited electron-transparent areas in cytoplasm due to losing 
most of organells. Some bacterial cells showed distortion of cell wall and broken 
cells. Figure 32 shows the micrographs of log phase cells of clinical isolates of 
CREnC after treatment with 10 μg/ml ceftazidime plus 10 μg/ml apigenin. Most of    
bacteria showed obvious detachment of cell wall and cytoplamic membrane. Also, 
electron-transparent areas were appeared in cytoplasm due to losing of ribosomes and 
other organells.  
           Discussion 
              From these results, it can conclude that both selected antibacterial drugs or 
flavonoids had little activity against MRSA or CREnC when use singly. However the 
combination of these drugs and flavonoids showed obvious great synergism activity 
against both strains, result in morphological damage. Many previous researchers 
reported the antibacterial activities of β-lactam plus flavonoid. These caused marked 
morphological damage to cells. The damage including loosening or detachment of 
outer membrane which may have resulted from damage to the peptidoglycan layer 
internal to the OM. Some of the bacteria exhibited electron-transparent areas devoid 
of ribosomes in the cytoplasm. Most of the treated bacteria were considerably larger 
and longer than the control bacteria. This results are in substantial agreement with 
those obtained with different bacterial species by Richards et al. (1993C) and 
Richards et al. (1996). The found that selected β-lactam plus selected flavonoids had 
an effect on the production of peptidoglycan in E. cloacae. These results are also in 
substantial agreement with those of Zhu (1995) who reported that detachment of the 
outer membrane from the cytoplasmic membrane of E. coli 326 cells after treatment 
with either SD and/or TMP.  
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Figure 15 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth: (a), (b), control (no antibacterial agent). Bar = 0.9 μm (a);  
0.3 μm (b) 
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Figure 16 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), cloxacillin (20 μg/ml). Bar = 0.9 μm 
(a); 0.3 μm (b) 
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Figure 17 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), ampicillin (20 μg/ml). Bar = 0.9 μm  
(a); 0.3 μm (b) 
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Figure 18 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), ceftazidime (20 μg/ml): I =  Larger gap  
between cell wall and cell membrane. Bar = 0.3 μm (a), (b) 
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Figure 19 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), baicalein (20 μg/ml): I=Larger gap  
between cell wall and cell membrane. Bar = 0.5 μm (a); 0.3 μm (b) 
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Figure 20 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), galangin (20 μg/ml). Bar = 0.3 μm (a), 
(b) 
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Figure 21 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), quercetin (20 μg/ml). Bar = 0.9 μm (a);   
0.3 μm (b) 
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Figure 22 Utrathin sections of log phase of clinical isolates of MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), ampicillin (10 μg/ml) plus baicalein  
(10 μg/ml): I = Gap between cell wall and cell membrane: II, III = Electron-  
transparent area devoid of ribosomes. Bar = 0.3 μm (a), (b) 
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Figure 23 Utrathin sections of log phase of clinical isolates of  MRSA grown for 4 h 
in Mueller–Hinton broth containing: (a), (b), cloxacillin (10 μg/ml) plus baicalein  
(10 μg/ml): I, II, III, IV = Electron-transparent area devoid of ribosomes. Bar = 0.3  
μm (a); 0.2 μm (b) 
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Figure 24 Utrathin sections of log phase of clinical isolates of  MRSA grown for 4 h 
in  Mueller–Hinton broth containing: (a), (b), ceftazidime (10 μg/ml) plus baicalein  
(10 μg/ml); I, II:  Morphological damage of cell wall and cytoplasmic membrane; III:  
Lost of some organells from cytoplasm. Bar = 0.3 μm (a); 0.2 μm (b) 
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Figure 25 Utrathin sections of log phase of clinical isolates of  MRSA grown for 4 h 
in  Mueller–Hinton broth containing: (a), (b), ceftazidime (10 μg/ml) plus galangin  
 (10 μg/ml); I: Electron-transparent areas devoid of ribosome and lost of some 
organells from cytoplasm; II, III: Cell wall damage. Bar = 0.3 μm (a), (b) 
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Figure 26 Utrathin sections of log phase of clinical isolates of  MRSA grown for 4 h 
in  Mueller–Hinton broth containing: (a), (b), ceftazidime (10 μg/ml) plus   quercetin 
(10 μg/ml); I, III: Gap between cell wall and cytoplasmic membrane; II, IV: Electron-
transparent areas devoid of ribosomes and lost of some organells from cytoplasm; V: 
Morphological damage of cell wall and cytoplasmic membrane. Bar = 0.5 μm (a), 0.3 
μm (b) 
 
I              II 
     
III  
IV 
V 
  
  
 
 
 
 
 
 
 
 
 
                                                                  
                                                                  (a) 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   (b) 
 
Figure 27 Utrathin sections of log phase of clinical isolates of CREnC grown for 4 h    
in  Iso-sensitest broth. (a), (b), control (no antibacterial agent). Bar = 0.9 μm (a); 0.3 
µm (b) 
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Figure 28 Utrathin sections of log phase of clinical isolates of  CREnC grown for 4 h 
in Iso-sensitest broth. (a), (b), containing: (a), (b) ceftazidime (20 μg/ml); I, II: Gap 
between outer membrane and cytoplasmic membrane. Bar = 2 μm (a); 0.5 μm (b) 
 
 
 
                 I 
II 
  
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
                                                                     
                                                                  (a) 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     (b) 
 
 
Figure 29 Utrathin sections of log phase of clinical isolates of CREnC grown for 4 h 
in Iso-sensitest broth. (a), (b), containing: (a), (b) luteolin (20 μg/ml). Bar = 0.5 µm 
(a); 0.3 μm (b) 
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Figure 30 Utrathin sections of log phase of clinical isolates of CREnC grown for 4 h        
in Iso-sensitest broth. (a), (b), containing: (a), (b) apigenin (20 μg/ml). Bar = 2 µm (a) 
; 0.5 μm (b) 
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Figure 31 Utrathin sections of log phase of clinical isolates of  CREnC grown for 4 h     
in Iso-sensitest broth. (a), (b), containing: (a), (b), (c), (d) ceftazidime 10 μg/ml plus 
luteolin 10μg/ml; I, II, III: Electron-transparent areas in cytoplasm and losing most of 
organells; IV, V: Distortion of cell wall and broken cells. Bar = 0.5 μm (a), (b); 0.3 
μm (c), (d) 
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Figure 32 Utrathin sections of log phase of clinical isolates of  CREnC grown for 4 h 
in Iso-sensitest broth. (a), (b), containing: (a), (b), (c), (d) ceftazidime 10 μg/ml plus 
apigenin 10 μg/ml; I: Gap between outer membrane and cytoplasmic membrane; II: 
Distortion of cell wall; III: Electron-transparent areas in cytoplasm and losing most of 
organells; IV, V, VI: Detachment of cell wall and cytoplasmic membrane. Bar = 2 μm 
(a), (c); 0.3 μm (b), 0.5 μm (d) 
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4.6 Capillary electrophoresis 
              Quantification of MRSA and CREnc were performed by comparision of the 
peak areas of the individual compounds relative to those of the appropriate internal 
standard is shown in Figure 33. The migration time at 19.014 min. The peak area was 
49.8 mAU*s. 
                The separation electrophoregram by capillary electrophoresis (CE) of 
peptidoglycan-associated proteins from MRSA control cells plus albumin as internal 
standard is shown in Figure 34. A good separation of the analyte and the internal 
standard was achieved by the selected electrophoresis conditions within 20 min. The 
six major peptidoglycan-associated protein peaks were found at the migration times 
(the ratio of peak areas) 17.836 (0.14), 18.145 (0.02), 18.344 (0.16), 18.718 (0.17), 
19.091 (1), and 20.977 (0.03) respectively. The internal standard albumin was found  
at 19.091 min. The ratio of peak area in parenthesis means the OM-PG protein of each 
peak area divided by the IS peak area (OM-PG peak of each area/IS peak area). 
              The peptidoglycan-associated proteins of MRSA grown in ampicillin at 20  
µg/ml is demonstrated in Figure 35.  The five protein peaks were found at migration 
times (ratio of peak areas) 17.748 (2.02), 18.358 (4.28), 18.844 (0.44), 19.042 (1), and 
20.976 (1.95) respectively. The internal standard albumin was found at 19.042 min. 
The protein peak at 18.145 (0.02) of the control seems to be reduced of the ratio of 
protein peak area.  
               The peptidoglycan-associated proteins from MRSA exposured to cloxacillin 
at 20 µg/ml is shown in Figure 36. The four major protein peaks were found at  
migration times (the ratio of peak areas) 17.309 (0.16), 17.805 (0.40), 18.545 (1), and 
 
20.334 (33.2) respectively. Also, the second protein peak at 18.145 (0.02) of the 
control is likely to be reduced of the ratio of protein peak area.  
              The peptidoglycan-associated proteins from MRSA treatment with baicalein 
at 20 µg/ml is presented in Figure 37. It was found four major proteins peaks. The 
four protein peaks were found at migration times (the ratio of peak areas) 17.313 
(0.45), 17.770 (0.81), 18.393 (1), and  20.281 (0.45) respectively. The second protein 
peak at 18.145 (0.02) of the control is likely to be reduced of the ratio of proteins peak 
area.  
               The peptidoglycan-associated proteins from MRSA exposured to ampicillin 
plus baicalein, and cloxacillin plus baicalein at 10:10 µg/ml are showed in Figure 38 
and 39 respectively. After treated with ampicillin plus baicalein at 10:10 µg/ml, the 
appearance of four major protein peaks were found at migration times (the ratio of 
peak areas) 17.377 (0.18), 17.797 (0.22), 18.573 (1), and 20.295(0.11) respectively. 
Also, the second protein peak at 18.145 (0.02) of the control seems to be reduced of 
the ratio of protein peak area.  
               Figure 39 after treated with cloxacillin plus baicalein at 10:10 µg/ml, the 
appearance of four major protein peaks were found at migration times (the ratio of 
peak areas)  17.442 (0.58), 17.829 (0.37), 18.621 (1), and 20.319 (0.33) respectively. 
The second protein peak at 18.145 (0.02), the fourth protein peak at 18.718 (0.17) and 
the fifth protein peak at 19.091 (1) of the control seem to be reduced of the ratio of 
protein peak areas, but sixth protein peak at 20.319 (0.03) of the control seems to be 
increased of the ratio of protein peak area.  
              The peptidoglycan-associated protein profiles on CE for MRSA grown in 
ceftazidime at 20 µg/ml are shown in Figure 40. A separation of the analyte and the 
internal standard was achieved by the selected electrophoresis conditions within 20 
min. Three appeared major protein peaks were found at migration times (the ratio of 
peak areas) 17.282 (0.21), 17.829 (0.36), and 18.558 (1) respectively. The second 
protein peak at 18.145 (0.02), the fourth protein peak at 18.718 (0.17) and the sixth 
protein peak at 20.977 (0.03) of the control are likely to be disappeared of the ratio of 
protein peak areas. 
              The peptidoglycan-associated protein profiles on CE for MRSA grown in  
galangin at 20 µg/ml are shown in Figure 41. A separation of the analyte and the 
internal standard was achieved by the selected electrophoresis conditions within 20 
min. After treatment with galangin at 20 µg/ml, three major protein peaks were found 
at migration times (the ratio of peak areas) 17.485 (0.83), 17.864 (0.33), and 18.544 
(1) respectively. The third protein peak at 18.344 (0.16), the fourth protein peak at 
18.718 (0.17) of control are likely to be reduced of the ratio of protein peak areas, but 
the sixth protein peak at 20.977 (0.03) of the control seems to be disappeared of the 
ratio of protein peak area.  
               The peptidoglycan-associated protein profiles on CE for MRSA grown in  
galangin at 20 µg/ml are shown in Figure 42. A separation of the analyte and the 
internal standard was achieved by the selected electrophoresis conditions within 20 
min. After exposure to quercetin at 20 µg/ml, five major protein peaks were found at 
migration times (the ratio of peak areas) 17.414 (0.16), 17.947 (0.39), 18.334 (0.32), 
18.671 (1), and 20.428 (0.09) respectively. The second protein peak at 18.145 (0.02) 
of  the control is likely to be reduced of the ratio of protein peak area. 
               The peptidoglycan-associated proteins of MRSA after treatment with 
ceftazidime plus baicalein, ceftazidime plus galangin and ceftazidime plus quercetin  
at 10:10 µg/ml are shown in Figure 43, 44, and 45 respectively.  
               Figure 43 shows the peptidoglycan-associated proteins of MRSA after 
treatment with ceftazidime plus baicalein. Three major protein peaks were showed at 
migration times (the ratio of peak areas) 17.441 (0.22), 17.922 (0.25), and 18.702 (1) 
respectively. The second protein peak at 18.145 (0.02), the fourth protein peak at 
18.718 (0.17) and the sixth protein peak at 20.977 (0.03) of the control are likely to be 
reduced of the ratio of protein peak areas. 
              Figure 44 shows the peptidoglycan-associated proteins of MRSA after 
treatment with ceftazidime plus galangin at 10:10 µg/ml. Four major protein peaks 
were appeared at migration times (the ratio of peak areas) 17.450 (0.32), 17.973 
(0.57), 18.376 (0.35), and 18.711 (1) respectively. The second protein peak at 18.145 
(0.02) of the control seems to be reduced of the ratio of peak area. The sixth protein 
peak at 20.977 (0.03) of the control seems to be disappeared of the ratio of protein 
peak area. 
              Figure 45 shows the peptidoglycan-associated proteins of MRSA after 
treatment with ceftazidime plus quercetin at 10:10 µg/ml. Four major protein peaks 
were found at migration times (the ratio of peak areas) 17.466 (0.40), 17.882 (0.40), 
18.289 (0.37), and 18.606 (1) respectively. The second protein peak at 18.145 (0.02) 
of the control seems to be reduced of the ratio of protein peak area. In addition, the 
sixth protein peak at 20.977 (0.03) of the control is likely to be disappeared of the 
ratio of protein peak area.  
              The separation electropherogram by capillary electrophoresis of 
peptidoglycan-associated proteins from CREnC cells control plus albumin as internal 
standard is shown in Figure 46. A separation of the analyte and the internal standard 
was achieved by the selected electrophoresis conditions within 20 min. The five major  
protein peaks were showed at migration times (the ratio of peak areas) 16.918 (0.21), 
17.421 (1.02), 18.125 (4.38), 18.831 (1), and 20.555 (0.31) respectively.  
              Figure 47 is presented the peptidoglycan-associated proteins peaks of 
CREnC after treatment with ceftazidime at 20 µg/ml. Four major protein peaks were 
showed at migration times (the ratio of peak areas) 16.925 (0.23), 17.402 (0.77), 
17.983 (1.08), and 18.760 (1) respectively. The second protein peak at 17.421 (1.02), 
the third protein peak at 18.125 (4.38) of the control seem to be reduced of the ratio of 
protein peak areas. Also, the fifth protein peak at 20.555 (0.31) of the control is likely 
to be disappeared of the ratio of protein peak area. 
              Figure 48 is showed the peptidoglycan-associated proteins peaks of CREnC 
after exposured to apigenin at 20 µg/ml. Three major proteins peaks were showed at 
migration times (the ratio of peak areas) 18.323 (0.80), 18.796 (3.05), and 19.602 (1) 
respectively. The first protein peak at 16.918 (0.21), the second  protein peak at 
17.412 (1.02) and the  third protein peak at 18.125 (4.38) of the control seem to be 
reduced of the ratio of protein peak areas. Morever, the fifth protein peak at 20.555 
(0.31) of the control is likely to be disappeared of the ratio of protein peak area.  
              Figure 49 is presented the peptidoglycan-associated proteins peaks of 
CREnC after treatment with luteolin at 20 µg/ml. There were three major proteins 
peaks by CE at migration times (the ratio of peak areas) 17.1 (0.15), 17.85 (0.15), 
18.452 (0.27), and 19.112 (1) respectively. The second protein peak at 17.412 (1.02) 
and the third protein peak at 18.125 (4.38) of the control seem to be clearly reduced of 
the ratio of protein peak areas. In addition, the fifth protein peak at 20.555 (0.31) of 
the control is likely to be disappeared of the ratio of protein peak area. 
 
 Figure 50 and 51 are showed the peptidoglycan-associated protein from 
CREnC after treatment with ceftazidime plus luteolin and apigenin at 10:10 µg/ml 
and 10:10 µg/ml respectively.  
              Figure 50 is presented the peptidoglycan-associated protein peaks of CREnC 
after treatment with ceftazidime plus luteolin. The results showed four major protein 
peaks at migration times (the ratio of peak areas) 16.931 (0.09), 17.666 (0.12), 18.677 
(0.54), and 19.009 (1) respectively. The first protein peak at 16.918 (0.21), the second 
protein peak at 17.421 (1.02) and the third protein peak at 18.125 (4.38) of the control 
seem to be reduced of the ratio of protein peak areas.  The fifth protein peak at 20.555 
(0.31) of the control is likely to be disappeared of the ratio of protein peak area. 
However, the fourth protein peak at 18.831 (1) of the control seem to be increased of 
the ratio of protein peak area. 
              Figure 51 is showed the peptidoglycan-associated protein peaks of CREnC 
after treatment with ceftazidime plus apigenin at 10:10 µg/ml. The result showed that 
three major protein peaks were appeared at migration times (the ratio of peak areas) 
16.978 (0.09), 17.662 (0.16), 18.794 (0.32), and 19.111 (1) respectively. The first 
protein peak at 16.918 (0.21), the second protein peak at 17.421 (1.02) and the third 
protein peak at 18.125 (4.38) of the control seem to be reduced of the ratio of protein 
peak areas. The fifth protein peak at 20.555 (0.31) of the control is likely to be 
disappeared of the ratio of protein peak area. But the fourth protein peak at 18.831 (1) 
of the control seems to be increased of the ratio of protein peak area. 
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 Figure 33 Electrophoregram of the separation by capillary electrophoresis 
of peptidoglycan-associated protein of  albumin  100 µg/ml as  internal                  
standard. The separation was carried out a fuse silica capillary, 50 µm I.D.,  
65 cm in total  length and 45 cm separat ion distance;  buffer  50 mM  
disodium tetraborate pH 9.1,detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 34  Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  control cells plus albumin as internal 
standard. The separation was carried out a fuse silica capillary, 50 µm I.D., 65 cm in   
total length and 45 cm separation distance; buffer 50 mM disodium tetraborate pH 
9.1; detection at 205 nm; injection, 8 s at 5kV; separation voltage 20 kV; IS = Internal  
standard 
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Figure 35 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with ampicillin at 20 µg 
/ml plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm  in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate; pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 36 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with cloxacillin at 20 
µg/ml plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm  in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate;  pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 37 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with baicalein at 20 µg/ml 
plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm  in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate;  pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 38 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with ampicillin plus 
baicalein at 10:10 µg/ml and plus albumin as  internal standard. The separation was 
carried out a fuse silica capillary, 50 µm I.D., 65 cm in total length and 45 cm 
separation distance; buffer 50 mM disodium tetraborate;  pH 9.1; detection at 205 nm; 
injection, 8 s at 5 kV;separation voltage 20 kV; IS = Internal standard 
 
 
 
D
et
ec
to
r 
re
sp
on
se
 (m
A
U
)
 
IS 
  
                                                                             Time (min) 
 
Figure 39 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with cloxacillin plus 
baicalein at 10:10 µg/ml and  plus albumin as  internal standard. The separation was 
carried out a fuse silica capillary, 50 µm I.D., 65 cm   in total length and 45 cm  
separation distance; buffer 50 mM disodium  tetraborate;  pH 9.1; detection at 205 
nm; injection, 8 s at 5 kV; separation voltage 20 kV; IS = Internal standard 
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Figure 40 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with ceftazidime at 20 
µg/ml plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate; pH 9.1; detection at 205 nm; injection, 8 s at 5 kV; 
separation voltage 20 kV; IS = Internal standard 
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Figure 41 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with galangin at 20 µg/ml 
plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm  in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate;  pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 42 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of  MRSA  after treament with quercetin at 20 µg/ml 
plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm  in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate;  pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 43 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA  after treament with ceftazidime plus 
baicalein at 10:10 µg/ml and plus albumin as  internal standard. The separation was 
carried out a fuse silica capillary, 50 µm I.D., 65 cm in total length and 45 cm 
separation distance; buffer 50 mM disodium tetraborate;  pH 9.1; detection at 205 nm; 
injection, 8 s at 5 kV; separation voltage 20 kV; IS = Internal standard 
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Figure 44 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA after treament with ceftazidime plus 
galangin at 10:10 µg/ml and plus albumin as internal standard. The separation was 
carried out a fuse silica capillary, 50 µm I.D., 65 cm in total length and 45 cm 
separation distance; buffer 50 mM disodium tetraborate; pH 9.1; detection at 205 nm; 
injection, 8 s at 5 kV; separation voltage 20 kV; IS = Internal standard 
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Figure 45 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of MRSA after treament with ceftazidime 
combined quercetin at 10:10 µg/ml and plus albumin as internal standard. The 
separation was carried out a fuse silica capillary, 50 µm I.D., 65 cm in total 
length and 45 cm separation distance; buffer 50 mM disodium tetraborate; pH 
9.1; detection at 205 nm; injection, 8 s at 5 kV; separation voltage 20 kV; IS = 
Internal standard 
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Figure 46  Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of CREnC  control cells plus albumin as internal 
standard. The separation was carried out a fuse silica capillary, 50 µm I.D., 65 cm in 
total lengt h and 45 cm separation distance; buffer 50 mM disodium tetraborate pH 
9.1; detection at 205 nm; injection, 8 s at 5kV; separation voltage 20 kV; IS = Internal  
standard 
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Figure 47 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of CREnC  after treament with ceftazidime  at 20 
µg/ml plus albumin as  internal standard. The separation was carried out a fuse silica 
capillary, 50 µm I.D., 65 cm  in  total length and 45 cm separation distance; buffer 50 
mM disodium tetraborate pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 48 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of CREnC after treament with apigenin at 20 µg/ml 
plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm; I.D., 65 cm  in total length and 45 cm separation distance; buffer 50 
mM disodium tetraborate, pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20kV; IS = Internal standard 
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Figure 49 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of CREnC  after treament with luteolin at 20 µg/ml 
plus albumin as  internal  standard. The separation was carried out a fuse silica 
capillary, 50 µm  I.D., 65 cm  in total length and 45 cm  separation distance; buffer 50 
mM disodium tetraborate;  pH 9.1; detection at 205 nm; injection, 8 s at 5 kV;  
separation voltage 20 kV; IS = Internal standard 
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Figure 50  Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of CREnC  after treament with ceftazidime plus 
luteolin at 10:10 µg/ml and plus albumin as internal standard.The separation was 
carried out a fuse silica capillary, 50 µm I.D., 65 cm in total length and 45 cm 
separation distance; buffer 50 mM disodium tetraborate pH 9.1; detection at 205 nm; 
injection, 8 s at 5 kV; separation voltage 20 kV; IS = Internal standard 
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Figure 51 Electrophoregram of the separation by capillary electrophoresis of 
peptidoglycan-associated protein of CREnC after treament with ceftazidime plus 
apigenin at 10:10 µg/ml plus albumin as  internal standard. The separation was carried 
out a fuse silica capillary, 50 µm; I.D., 65 cm in total length and 45 cm separation 
distance; buffer 50 mM disodium tetraborate, pH 9.1; detection at 205 nm; injection,  
8 s at 5 kV; separation voltage 20 kV;  IS = Internal standard 
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            Discussion 
              The result in Figure 33 shows that electrophoregram of MRSA control cells 
albumin as internal standard had six major OM-PG associated protein peak areas at 
migration time 17.836 (0.14), 18.415 (0.02), 18.344 (0.16), 18.718 (0.17), 19.019 (1), 
and 20.977 (0.03) respectively. Whereas, Electrophoregram of MRSA when treated 
with ampicillin:baicalein (10:10 µg/ml) showed migration times at 17.377 (0.18), 
17.797 (0.23), 18.573 (1), and 20.295 (0.11) respectively. It was found that the 
absence and/or reduction of medium MW protein peak areas and increasing in higher 
and lower MW protein peak areas when compared to control cells. This result was 
almost the same as MRSA treated cells with cloxacillin:baicalein (10:10 µg/ml) in 
Figure 39. In addition the extracted OM-PG associated protein peak areas of this 
MRSA strain treated with ceftazidime:baicalein (10:10 µg/ml) in Figure 43 shows the 
migration times at 17.441 (0.14), 17.922 (0.25), and 18.702 (1) respectively. The 
combination of ceftazidime plus baicalein MRSA treated cells showed that the 
absence and/or reduction of medium and lower MW protein peak areas and increasing 
in higher MW protein peak areas when compared to control cells. This results were 
approximately the same as the results of MRSA cells after treatment with ceftazidime 
:galangin (10:10 µg/ml) or ceftazidime:quercetin (10:10 µg/ml).  
              The electrophoregram of CREnC control cells in Figure 46 shows the 
migration times (the ratio of the peak areas) at 16.918 (0.21), 17.412 (1.02), 18.125 
(4.38), 18.831 (1), and 20.555 (0.3) respectively. While the results of OM-PG 
associated protein extracts of this strain when expose to ceftazidime 10 µg/ml plus 
luteolin or apigenin at 10 µg/ml clearly showed the absence and/or reduction of both 
higher and lower MW protein peak areas when compared to the CREnC control cells.        
              The overall results presented here are also in substantial agreement with 
those obtained by Leying et al. (1986) with E. coli   D509 grown in 1/4 and 1/6 the 
MICs of moxalactam. Moxalactam induced a strong reduction of the heavier OM 
protein bands. The results are also in agreement with those of Suerbaum and co-
worker (1987) who concluded that imipenam, cephaloridine and ciprofloxacin had 
pronounced effects on the quantitative composition of the OM and the capsule 
information of E. coli. These β- lactams and ciprofloxacin seem to induce marked 
changes of the quantitative composition of the cell enveloped of E. coli and the 
phospholipid/amino acid ratio was reduced in almost all OM preparation from 
bacteria treated with the antibacterials. 
               These results may invole two mechanisms of actions. The first is on the 
integrity to the cell wall and on septum formation prior to cell division, the implies an 
effect on protein synthesis including an effect on penicillin-binding proteins. The 
second mechanism of β-lactam activity is via inhibition of the activity of certain β-
lactamase enzymes. The first could also include an affect on the production and/or 
release of β-lactamase enzyme within and from the cell walls (Yam et al., 1998).  
 
 
 
 
 
 
4.7 Enzyme assay 
              The ability of flavonoids plus selected β-lactam antibacterial to inhibit in 
vitro activity of β-lactamases varies considerably. Figure 52 indicated that the 
flavonoids had an inhibitory activity against β-lactamase I from B. cereus. Baicalein 
had some activity.   Baicalein and quercetin in combination at 10 min showed greater 
activity. Figure 53 shows the ability of baicalein to inhibit in vitro activity of β-
lactamase to break ampicillin structure. The result showed that baicalein plus 
ampicillin can inhibit in vitro of β-lactamase activity.  Figure 54 indicated that 
baicalein plus cloxacillin had some activity against β-lactamase to break cloxacillin 
structure. Figure 55 shows activity of apigenin or luteolin against β-lactamase type IV 
from E. cloacae, that can cleave β-lactam bond of ceftazidime. Apigenin showed 
marked inhibitory activity. Moreover, luteolin showed greater activity. 
                       These results indicated that the combination of ceftazidime plus galangin 
or quercetin or baicalein, ampicillin plus baicalein and cloxacillin plus baicalein not 
only had direct effect on cell structure and cell division but also inhibited β-lactamase 
activity from B. cereus. Furthermore ceftazidime plus luteolin or apigenin showed 
marked inhibitory activity against β-lactamase from E. cloacae. The resistance 
reversing activity of flavonoids against these bacteria might also include inhibition of 
β-lactamase activity. 
 
           Discussion 
              These results indicated that flavonoids not only have an activity of their own 
against β-lactam resistant bacteria but also have the ability to reverse the resistance of 
such bacterial strains to the activity of the primary antibiotics. This may involve two 
mechanisms of action by the flavonoids. The first is on the integrity of the cell wall 
and on septum formation prior to cell division. This implies and effect on protein 
synthesis including an effect on penicillin-binding proteins. 
              The second mechanism of β-lactam activity is via inhibition of the activity of 
certain β-lactamase enzymes. The first action could also include an effect on the 
production and/or release of β-lactamase enzymes within and from the cell walls  
(Yam et al., 1998). In the last two decades, β-lactamase inhibitors like clavulanic acid 
have played an important role in fighting β-lactam resistant bacteria. 
              These inhibitors work as suicide compound react with enzyme since they 
share the same key struct with β-lactam antibiotics (Coulton and Francois, 1994). 
Recent studies demonstrated that clavulanate caused a considerable induction of β-
lactamase expression and an increase of clavulanate concentration was followed by an 
elevation in β-lactamase production (Staplefon et al., 1995; Tzouvelekis et al., 1997). 
              These results may be explained that the presently available β-lactamase 
inhibitors can also lose their activity by the same mechanicm as the β-lactam 
antibiotics. For this research provides an unique example that flavonoids without a β-
lactam structure can reverse bacterial resistance to β-lactams via multiple 
mechanisms. Because of this structural dissimilarity these compounds are unlikely to 
induce β-lactamase production. It should also be rememberd that conventional β-
lactamase inhibitors, unlike flavonoids cannot reverse the resistant of MRSA, which 
is one of the most dangerous bacterial pathogen ( Griangsak Eumkeb and Richards, 
2004).  
   
 
                                  
 
 
 
 
 
 
                 Figure 52 The inhibitory activity of flavonoids against β-lactamase in       
                 hydrolyzing ceftazidime. β-lactamase used from B. cereus; symbol  
                 represents flavonoids (200 μg/ml); ●, control(without flavonoids); ▲                     
                 galangin; ■, quercetin; ♦, baicalein 
 
 
 
 
0
100
200
300
400
500
Time (min)
0 20 10 
C
ef
ta
zi
di
m
e 
( μg
/m
l)
  
 
              
                    Figure 53 The inhibitory activity of flavonoids against β-lactamase in   
                 hydrolyzing ampicillin. β-lactamase used from B.cereus; symbol  
                 represents flavonoids (200 μg/ml); ■, control (without flavonoids);  
                 ♦, baicalein                    
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               Figure 54 The inhibitory activity of flavonoids against β-lactamase in  
             hydrolyzing cloxacillin. β-lactamase used from B. cereus; symbol  
             represents flavonoids (200 μg/ml); ■, control (without flavonoids);   
            ♦, baicalein 
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                     Figure 55 The inhibitory activity of flavonoids against β-lactamase in  
                      hydrolyzing ceftazidime. β-lactamase used from E. cloacae; symbol         
                      reoresents flavonoids (200 μg/ml); ▲, control (without flavonoids); ■,   
                      apigenin; ♦, luteolin 
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                                               CHAPTER V 
                                  CONCLUSION  
 
    
              Presently, there is an emergence of multiple drug resistance to human 
pathogenic organisms. Thus, development of a new antibacterial agents is urgently 
needed, especially anti-MRSA and CREnC agents that these bacterial caused 
nosocomial infections increasing. One approach is to search for new inexpensive and 
effective antibacterial agents from new sources, especially from plants, for possible 
antimicrobial properties. The present work, flavonoids from plants such as apigenin, 
baicalein, galangin, luteolin and quercetin plus β-lactam antibiotics were tested 
against methicillin-resistant S. aureus (MRSA) and ceftazidime-resistant E. cloacae 
(CREnC).These clinical isolates of bacteria caused high percentage of drugs-
resistance in many sections of the local hospitals and worldwide, as a result, the cost 
of treating these infection diseases are increasing.  
               The results from this study showed that two clinical isolated strains (MRSA 
and CREnC) were resistant to all selected β-lactam antibiotics (ampicillin, cloxacillin 
and ceftazidime). All tested flavonoids showed no activity against all clinical isolates 
strains (MRSA, CREnC and ASEnC) when used alone. However, significant 
synergistic activities against both MRSA and CREnC in combination with β-lactam 
antibiotics were observed. In checkerboard test, the results showed that when 
combined  ampicillin, cloxacillin and ceftazidime  with baicalein 5 µg/ml, minimum 
inhibitory concentrations (MICs) of these drugs against clinical isolates of MRSA 
were reduced from 100, > 1,000, and 50 µg/ml to 5, 5, and 5 µg/ml respectively. 
Furthermore, clinical isolates of CREnC with MIC of ceftazidime > 1,000 µg/ml had 
their resistance to these drugs reversed by apigenin 5 µg/ml or luteolin 5 µg/ml to 
MIC of ceftazidime 5 µg/ml. Viable counts showed that the  killing of MRSA cells by 
10 µg/ml ampicillin or cloxacillin was potentialed by 10 µg/ml baicalein. Ceftazidime 
10 µg/ml in combination with 10 µg/ml of baicalein or galangin or quercetin also 
reduced the CFU/ml of MRSA to low level (1Х103 CFU/ml) over 6 h. These results 
are in substantial agreement with those of Iain (2000) that the baicalein had the 
potential to restore the effectiveness of β-lactam antibiotics against MRSA. The 
results seem consistent with Sato et al. (2004) that 6, 7 dihydroxyflavone 
synergistically elevates the susceptibility of MRSA to β-lactam antibiotics from 8 t0 
32,000 fold. Morever flavone found to show diverse synergistic effects on the 
susceptibility of MRSA to β-lactam antibiotics. The killing curve of CREnC cells 
were also maintained at low level from 6 to 24 h by ceftazidime 10 µg/ml in 
combination with 10 µg/ml of luteolin or apigenin.  
               Electronmicroscopy clearly showed that the combination of 10 µg/ml 
baicalein with 10 µg/ml of ampicillin or cloxacillin caused electron-transparent areas 
devoid of ribosomes (hole) clearly visible within the cytoplasm. A lot of cells lost 
some organelles from cytoplasm such as ribosome, chromosomes etc. Some of these 
showed morphological damages such as cell wall and cell shape distortion. Broken of 
some cells were also observed. Morever, the combination between 10 µg/ml 
ceftazidime with 10 µg/ml of baicalein or galangin or quercetin caused damage to the 
ultrastructure of MRSA such as cell wall damage, electron-transparent areas devoid of 
ribosomes and lost some organelles from cytoplasm. The results seem consistent with 
Eumkeb and Richards (2005) that the combination of β-lactam with galangin caused 
damage to the ultrastructural of MRSA cells. In addition, the results showed that 
ceftazidime 10 µg/ml in combination with 10 µg/ml of luteolin or apigenin also 
caused marked morphological damage for CREnC. A lot of these bacterial cells 
exhibited morphological damage of cell wall, cell shape and electron-transparent 
areas in cytoplasm due to losing most of organelles. Several bacterial cells showed 
broken cell and distortion of cell wall. Some of these cells showed obvious 
detachment of cell wall and plasma membrane.  
               In addition, Electrophoregrams show that the extracted OM-PG associated 
protein peak areas of clinical isolates of MRSA exposed to either ampicillin:baicalein 
(10:10 µg/ml) or cloxacillin:baicalein (10:10 µg/ml) showed the absence and/or 
reduction of medium MW protein peak areas and increasing in higher and lower MW 
protein peak areas. Similarly, the extracted OM-PG associated protein peak areas of  
this MRSA strain treated with either ceftazidime:baicalein (10:10 µg/ml), 
ceftazidime:galangin (10:10 µg/ml) or ceftazidime:quercetin (10:10 µg/ml) exhibited 
the absence and/or reduction of medium and lower MW protein peak areas and 
increasing in higher MW protein peak areas. Results from electrophoregrams of OM-
PG associated protein extracts of CREnC strains when exposed to ceftazidime 10 
µg/ml plus luteolin or galangin at 10 µg/ml showed the absence and/or reduction of 
both higher and lower MW protein peak areas. These absence and/or reduction of 
medium and higher (or lower) MW OM-PG associated proteins in MRSA and CREnC 
respectively probably led to the marked morphological damage, detachment of OM 
and peptidoglycan, the longer and wider cell size in both strains. The results from 
electrophoregrams seem consistent with the results from checkerboard, viable counts 
and TEM. 
              The results from enzyme assay indicated that β-lactamase activity of B. 
cereus was inhibited by the combinations of  ceftazidime plus galangin or quercetin or 
baicalein and baicalein plus  ampicillin or cloxacillin. Morever the β-lactamase 
activity of E. cloacae was marked inhibited by the combinations of ceftazidime plus 
luteolin or apigenin. The resistance reversing activity of selected flavonoids against 
these bacteria might also include inhibition of β-lactamase activity. These results are 
in substantial agreement with earier finding suggesting that flavonoids not only have 
an activity of their own against β-lactam resistant bacteria but also have the ability to 
reverse the resistance of these bacterial strains to the activity of the primary 
antibiotics. This may invole two mechanisms of action by the flavonoids. The first is 
on the integrity of the cell wall and on septum formation prior to cell division. The 
second is on the mechanism of β-lactamase enzymes (Yam et al., 1998). 
              From this study, it was concluded that baicalein, galangin and quercetin have 
the potential to reverse bacterial resistance to β-lactam antibiotics against MRSA. 
Luteolin and apigenin have synergistic effect with ceftazidime against CREnC. In 
view of their limited toxicity, these tested flavonoids offer for the development of a 
valuable adjunct to β-lactam treatments against otherwise resistant strains of currently 
almost untreatable microorganisms.  
          
Future Work 
1. In vivo toxicity test of selected flavonoids and/or plus selected 
antibacterials. 
2. Determination of the sequence of amino acids in the polypeptides in 
each OM-PG associated protein band in MRSA and CREnC strains by 
using chemical and the Edman degradation method or an automated 
device such as a sequentor. Then, comparing the amino acid content of a 
polypeptide hydrolysate, which can be quantitatively determined by 
using an automated amino acid analyzer for each OM-PG associated 
protein band of the control cells and treated cells.  By these methods the 
sequence of amino acid in each protein band of the control cells and 
treated cells may be compared. The amino acid sequences that combine 
to from polypeptides (proteins) in each protein band could also be 
determined. This would elucidate further the mechanism of action of 
antibacterials. 
3. Evaluate the effects of other antimicrobial combination such as other β-
lactam antibiotics plus flavonoids. 
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